書籍詳細

炎症リウマチ

P.6 掲載の参考文献

• 1) 大田 寛. 慢性関節リウマチ患者の死因と壽命. リウマチ病セミナーIII (七川歡次監修), 1992;85-94, 大阪, 永井書店.

• 2) Maradit-Kremers H, Crowson CS, Nicola PJ et. al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis:a population-based cohort study. Arthritis Rheum 2005; 52 (3):402-11.

• 3) Nicola PJ, Maradit-Kremers H, Roger VL et. al. The risk of congestive heart failure in rheumatoid arthritis. Arthritis Rheum 2005; 52 (3):412-420.

• 4) 志水正敏. ストレスと慢性関節リウマチ. リウマチ病セミナーIX (七川歡次監修), 1993;31-37, 大阪, 永井書店.

• 5) 志水正敏. 環境とリウマチ病. リウマチ病セミナーXII 2001; 97-105, 大阪, 永井書店.

• 6) 志水正敏. 関節リウマチと閉塞性睡眠障害. リウマチ病セミナーXVI (七川歡次監修), 2003; 194-202, 大阪, 永井書店.

• 7) 澤井高志. 関節リウマチ (RA) における心病変. 近畿リウマチ病研究会講演集 2006; 47-55.

• 8) 福田純也. 関節リウマチの剖検例における心病変. 第17回近畿リウマチ病研究会講演集 2007; 51-56.

• 9) 百村伸一. 睡眠時無呼吸と循環器疾患. 第17回近畿リウマチ病研究会講演集 2007; 41-49

• 10) 成井浩司. 睡眠時無呼吸症候群と循環器疾患. JOHNS 2006; 22 (6):803-812.

• 11) 志水正敏. 上気道抵抗症候群. リウマチ病セミナーXVII (七川歡次監修), 2006; 7682, 大阪, 永井書店.

• 12) Phillipson EA, Bowes G. Sleep disorder. Update:Pulm Diseases and Disorders. 1982,:256-273, New York, McGraw-Hill.

P.18 掲載の参考文献

• 1) Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332:139-142.
  pubmed

• 2) Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-1131.
  pubmed

• 3) Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352 (9131):878.
  pubmed

• 4) Gasbarrini A, Franceschi F. Autoimmune diseases and Helicobacter pylori infection. Biomed Pharmacother 1999; 53:223-226.
  pubmed

• 5) Takahashi T, Yujiri T, Shinohara K, Inoue Y, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004; 124:91-96.
  pubmed

• 6) Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97:812-814.
  pubmed

• 7) Forman D, Sitas F, Newell DG, et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990; 46:608-611.
  pubmed

• 8) Janulaityte-Gunther D, Gunther T, et al. What Bizzozero never could imagine-Helicobacter pylori today and tomorrow. Medicina 2003; 39:542-549.
  pubmed

• 9) Rickes S, Schultze U, Monkemuller K, et al. Walter Krienitz-his life and intuitive description of bacteria in the stomach. Dtsch Med Wochenschr 2006; 131:1341-1343.
  pubmed

• 10) Kidd M, Modlin IM. A century of Helicobacter pylori:paradigms lost-paradigms regained. Digestion 1998; 59:1-15.
  pubmed

• 11) Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i. 1983; 1273.
  pubmed

• 12) Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388:539-547. Erratum in:Nature 1997; 389 (6649):412.

• 13) 日本ヘリコバクター学会ガイドライン作成委員会. H. pylori感染の診断と治療のガイドライン2003年改訂版. 日本ヘリコバクター学会誌 2003 4 (suppl):2-16.
  Medical*Online

• 14) Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006;19:CD003840.

• 15) Inagaki H, Nakamura T, Li C, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004; 12:1560-1567.
  pubmed

• 16) Appelmelk BJ, Negrini R, Moran AP, et al. Molecular mimicry between Helicobacter pylori and the host. Trends Microbiol 1997; 2:70-73.
  pubmed

• 17) Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160:1630-1638.
  pubmed

• 18) Vesely SK, Perdue JJ, Rizvi MA et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy:a systematic review. Ann Intern Med 2004; 140:112-120.
  pubmed

• 19) Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 2001; 115:1002-1003.
  pubmed

• 20) Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 2002; 118:584-588.
  pubmed

• 21) Hino M, Yamane T, Park K, et al. Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura. Ann Hematol 2003; 82:30-32. Epub 2002 Dec 17.

• 22) Hashino S, Mori A, Suzuki S, et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol 2003; 77:188-191.
  pubmed

• 23) Ando K, Shimamoto T, Tauchi T, et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol 2003; 77:239-244.

• 24) Michel M, Cooper N, Jean C, et al. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 2004; 103:890-896. Epub 2003.
  pubmed

• 25) Takahashi T, Yujiri T, Tanizawa Y. Helicobacter pylori and chronic ITP:the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood 2004; 104:594.
  pubmed

• 26) Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005; 81:162-168.
  pubmed

• 27) Ando T, Tsuzuki T, Mizuno T, et al. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter 2004; 9:443-452.
  pubmed

• 28) Sato R, Murakami K Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 2004; 164:1904-1907.
  pubmed

• 29) Inaba T, Mizuno M, Take S, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest 2005; 35:214-219.
  pubmed

• 30) Veneri D, Krampera M, Franchini M. High prevalence of sustained remission of idiopathic thrombocytopenic purpura after Helicobacter pylori eradication:along-term follow-up study. Platelets 2005; 16:117-119.

• 31) Stasi R, Rossi Z, Stipa E, et al. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 2005; 118:414-419.
  pubmed

• 32) Suzuki T, Matsushima M, Masui A, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 2005; 100:1265-1270.
  pubmed

• 33) Suvajdzic N, Stankovic B, Artiko V, et al. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets 2006; 17:227-230.
  pubmed

• 34) 藤村欣吾. 免疫性血小板減少性紫斑病 (ITP) における治療ガイドラインの提案-ヘリコバクタピロリ除菌療法の成績をふまえて-厚生労働省科学研究費補助金 難治性疾患克服事業 平成16年度 総括・分担研究報告書血液凝固異状症に関する調査研究, 2005; 53-69.

• 35) Wilson KT, Fantry GT. Pathogenesis of Helicobacter pylori infection. Curr Opin Gastroenterol 1999; 15:66-71.
  pubmed

• 36) Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003; 124:184-1854.

P.30 掲載の参考文献

• 1) Dalinka MK, Melchior EL. Soft tissue calcifcations in systemic disease. Bull N Y Acad Med 1980; 56:539-563.

• 2) 圓尾宗司:透析に関連して出現するリウマチ症状. リウマチ病セミナーXI (七川歡次監修), 2000, p66-75, 大阪, 永井書店.

• 3) 橋本淳:myositis ossificans progressiva, リウマチ病セミナーXI (七川歡次監修), 2000, p45-51, 大阪, 永井書店.

• 4) 石澤命仁:myositis ossificans, リウマチ病セミナーXIV (七川歡次監修), 2003, p29-35, 大阪, 永井書店.

• 5) Akiyama Y, Tanaka M, Takeishi M, et al. Clinical, serological and genetic study in patients with CREST syndrome. Internal Medicine 2000; 39:451-456.

• 6) Nishikai M, Itoh K, Sato A. Calcinosis and the anticentromere antibody:its clinical, radiological and immunogenetic aspects. Br J Rheumatol 1992; 31:9-12.
  pubmed

• 7) Miyawaki S, Asanuma H, Nishiyama S, et al. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005; 32:1488-1494.
  pubmed

• 8) Tramposch HD, Smith CD, Senecal JL, et al. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984:27:121-124.
  pubmed

• 9) Chung CP, Oeser A Avalos I, et al. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15:562-569.
  pubmed

• 10) Molad Y, Levin-Iaina N, Vaturi M, et al. Heart valve calcification in young patients with systemic lupus erythematosus:a window to premature atherosclerotic vascular morbidity and a risk factor for all-cause mortality. Atherosclerosis 2006; 185:406-412.

• 11) 武井修治. 小児膠原病-その病態の特徴と成人例との違い. 臨床リウマチ 2002; 14:197-204.

• 12) Chien-Chang Lee, Yao-Hsu Yang, Bor-Luen Chiang. Cinical Images:Calcinosis universalis complicating juvenile dermatomyositis. Arthritis Rheum 2005; 52:1626.

• 13) 宮前多佳子, 森 雅亮, 稲毛康司, ら:若年性皮膚筋炎に併発する異所性石灰化の実態調査. リウマチ 2003; 43:538-543.

• 14) Pachman LM&Boskey AL. Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Current Rheumatol Reports 2006; 8:236243.

• 15) Pachman LM, Liotta-Davis MR, Hong DK et al. TNFα-308A allele in juvenile dermatomyositis. Arthritis Rheum 2000; 43:2368-2377.

• 16) Pachman LM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148:247-253.
  pubmed

• 17) Stock SR, lgnatiev K, Lee PL, et al. Pathological calcification in juvenile dermatomyositis (JDM):micro CT and synchrotron x-ray diffraction reveal hydroxyapatite with varied microstructures. Calcified Tis Res 2004; 45:248-256.

• 18) Pachman LM, Veis A, Stock S, et al. Composition of calcifications in children with juvenile dermatomyositis. Arthritis Rheum 2006; 54:3345-3350.
  pubmed

• 19) Campean V, Neureiter D, Nonnast-Daniel B, et al. CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis 2007; 190:156-166.
  pubmed

• 20) Wadwa RP, Kinney GL, Ogden L, et al. Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetes. Int J Biochem Cell Biol 2006; 38:996-1003.
  pubmed

• 21) Khan SR. Crystal-induced inflammation of the kidneys:results from human atudies, animal models, and tissue-culture stdies. Clin Exp Nephrol 2004, 8:75-88.

• 22) Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep 2003; 5:222-226.
  pubmed

• 23) Rider LG. Calcinosis in juvenile dermatomyositis:Pathogenesis and current therapies:66th Annual American College of Rheumatology Meeting, 2002 (New Orleans).

• 24) Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Amer Acad Derm 2002; 47:505-511.

• 25) Olson NY &Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16:1545-1547.
  pubmed

• 26) Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91:169-172.
  pubmed

• 27) Zeller V, Cohen P, Prieur AM, et al. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm folloeup of 6 cases. J Rheumatol 1996; 23:1424-1427.

• 28) Maillard SM, Wilkinson N, Riley P, et al. The treatment of persistent severe idiopathic inflammatory myositis with anti-TNFalpha therapy. Arthritis Rheum 2003; 46 (suppl):S307.

• 29) Fuchs D, Fruchter L, Fishel B, et al. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986; 5:527-530.
  pubmed

• 30) Hazen PG, walker AE, Camey JF, et al. Cutaneous calcinosis of scleroderma. Successful treatment with intralesional adrenal steroids. Arch Dermatol 1982; 118:366-367.

• 31) Berger RG, Featherstone GL, Raasch RH, et al. Treatment of calcinosis universalis with low-dose warfarin. Am JMed 1987; 83 (1):72-76.

• 32) Palmieri GMA, Sebes JI, Moinuddin M, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum 1995; 38:1646-1654.

• 33) Ichiki Y, Akiyama T, Shimozawa N, et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144:894-897.
  pubmed

• 34) Vayssairat M, Hidouche D Abdoucheli-Baudot N, et al. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 1998; 57:252-254.
  pubmed

• 35) Nakagawa T&Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol 1993; 20:558-560.
  pubmed

• 36) Harel L, Harel G, Korenreich L, et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid:the role of phosphorus metabolism in the development of calchications. J Rheumatol 2001; 28:1129-1132.
  pubmed

• 37) Nakamura H, Kawakami A, Ida H, et al. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol 2006; 33:1691-1693.
  pubmed

• 38) Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis:a study of composition and treatment. J Pediatr 2001; 138 (5):763-766.
  pubmed

• 39) 田中伴由起. ビスフォスフォネートの血管石灰化抑制作用. Medical Science Digest 2005; 31:407-411.

• 40) Shiraishi N, Kitamura K, Miyoshi T, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006; 48:151-154.
  pubmed

• 41) Ambler GR, Chaitow J Rogers M, et al. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005; 32:1837-1839.
  pubmed

• 42) Hill JA, Goldin JG, Gjertson D, et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 2002; 9:1148-1152.
  pubmed

• 43) Yokoyama M, Aono H, Takeda A, et al. Cimetidine for chronic calcifying tendonitis of the shoulder. Reg Anesth Pain med 2003; 28:248-252.
  pubmed

• 44) Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosos with minocycline. Ann Rheum Dis 2003; 62:267-269.

• 45) Okada J, Nomura M, Shirataka M, et al. Prevalence of soft tissue calcifications in patients with SLE and effects of alfacarcidol. Lupus 1999; 8:456-461.
  pubmed

• 46) Ebenbichler GR, Erdogmus CB, Resch KL, et al. Ultrasound therapy for calcific tendinits of the shoulder. N Engl J Med 1999; 340:1533-1538.

• 47) Chamberlain AJ & Walker NPJ. Successful palliation and significant remission of cutaneous calcinosos in CREST syndrome with carbon dioxide laser. Dermatol Surg 2003; 29:968-970.
  pubmed

• 48) Shearin JC & Pickrell K. Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis. Ann Plast Surg 1980; 5:381-385.
  pubmed

P.39 掲載の参考文献

• 1) Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis pateints with Disease-Modifying Antirheumatic Drug-induced clinical remission. Evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54:3761-3773.

• 2) Makinen H, Hannonen P, Sokka T. Definitions of remissin for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remissin. Clin Exp Rheumatol 2006; 24 (Suppl):S22-S28.

• 3) Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007; 34:316-321.
  pubmed

• 4) Ollier WER, Harrison B, Symmons D. What is the natural history of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001; 15:27-48.

• 5) 村田紀和, 前田 晃. 早期RAの手・足の変形予防に対する長期臨床研究 (第7報) . 昭和63年度特定疾患調査研究結果報告書. 1989; 骨47〜骨51.

• 6) Sesin CA, Bingham CO, III. Remission in rheumatoid arthritis:Wishful thinking or clinical reality? Semin Arthritis Rheum 2005; 35:185-196.
  pubmed

• 7) Wolfe F, Ross K, Hawley DJ, et al. The prognosis of rheumatoid arthritis and undifferenciated polyarthritis syndrome in the clinic:a study of 1141 patients. J Rheumatol 1993; 20:2005-2009.

• 8) Dougados M, Emery P, Lemmel EM, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis:RELIEF 6-month data. J Rheumatol 2003; 30:2572-2579.

• 9) Listing J, Strangfeld A Rau R, et al. Clinica and functional remission:even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8:R66, 2006.

• 10) Allaart CF, Goekoop-Ruiterman YPM, de Vries-Bouwstra, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies:the Best study. Clin Exp Rheumatol 2006; 24 (Suppl):S77-S82.
  pubmed

• 11) Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis. Defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625-2636.
  pubmed

• 12) Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006; 24 (Suppl):S7-S13.

• 13) Aletaha D, and Smolen JS. Remission of rheumatoid arthritis:should we care about definitions? Clin Exp Rheumatol 2006; 24 (Suppl):S45-S51.

P.49 掲載の参考文献

• 1) Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-1227.

• 2) Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan:nationwide questonnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28:554-559.

• 3) Feldkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23:61-66.
  pubmed

• 4) 村田紀和. 脊椎関節炎に対する生物学的製剤の効果. リウマチ病セミナー XVI (七川歡次監修). 2005; p214-221, 大阪, 永井書店.

• 5) Amor B, Dougados M, Mijiyama M. Criteres de classification des spondylarthropathies. Rev Rhum 1990; 57:85-89.

• 6) 辻本正記, 谷仁孝, 喜多貞夫, ら. SpondylarthropathyにおけるAmorのClassification criteriaの検討. リウマチ病セミナーII (七川歡次監修). 2001; p25-31, 大阪, 永井書店.

• 7) Boyer GS, Templin DW, Cornoni-Huntley JC, et al. Prevalence of spondyloarthropathies in Alaskan Eskimos. JRheumatol 1994; 21:2292-2297.
  pubmed

• 8) Mau W, Zeidler H, Mau R, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis:results of a 10-year followup. J Rheumatol 1988; 15:1109-1114.
  pubmed

• 9) Oostven J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography:a prospective longitudinal study. J Rheumatol 1999; 26:1953-1958.
  pubmed

• 10) Kumar A, Bansal M, Srivastava DN, et al. Long-term outcome of undifferentiated spondylarthropathy. Rheumatol Int 2001; 20:221-224.
  pubmed

• 11) Sampaio-Barros PD, Bertolo MB, Kraemer MH, et al. Undifferentiated spondyloarthropathy:a 2-year follow-up study. Clin Rheumatol 2001; 20:201-206.
  pubmed

• 12) Kellgren JH. Diagnostic criteria for population studies. Bulletin on the Rheumatic Diseases 1962; 13:291-292.
  pubmed

• 13) Bennett PH, Burch TA. Population studies of rheumatic diseases. Amsterdam:Excerpta Medica Foundations; 1968, p.456-457.

• 14) Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis:a proposal for modification of New York criteria. Arthritis Rheum 1984; 27:361-368.
  pubmed

• 15) Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis, JAMA 1977; 237:2613-2614.
  pubmed

• 16) Gran JT. An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 1985; 4:161-169.
  pubmed

• 17) Rudwaleit M, Metter A, Listing J, et al. Clinical parameters in the differentiation of inflammatory back pain from non-inflammatory back pain. Ann Rheum Dis 2002; 61 (suppl):57-57.

• 18) Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis:a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54:569-578.
  pubmed

• 19) Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995; 34:1074-1077.
  pubmed

• 20) Battafarano DF, West SG, Rak KM, et al. Comparison of bone scan, computed tomography, and magnetic resonance imaging in the diagnosis of active sacroiliitis. Semin Arthritis Rheum 1993; 23:161-176.
  pubmed

• 21) Puhakka KB, Jurik AG, Egund N, et al. Imaging of sacroiliitis in early seronegative spondylarthropathy:assessment of abnormalities by MR in comparison with radiography and CT. Acta Radiologica 2003; 44:218-229.
  pubmed

• 22) Shichikawa K, Tsujimoto M, Nishioka J, et al. Histopathology of early sacroiliitis and enthesitis in ankylosing spondylitis. In Advances in Inflammation Research. Vol 9:The Spondyloarthropathies (Ziff M, Cohen SB, eds), New York:Raven Press; 1985, p15-24.

• 23) Miron SD, Khan MA, Wiesen EJ, et al. The value of quantitative sacroiliac scintigraphy in detection of sacroiliitis. Clin Rheumatol 1983; 2:407-414.
  pubmed

• 24) 杉本英治. Spondyloarthropathyの画像診断. リウマチ科 2005; 34:559-566.

• 25) Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37:1039-1045.
  pubmed

• 26) Hanly JG, Mitchell MJ, Barnes DC, et al. Early recognition of sacroiliitis by magnetic resonance imaging and single photon emission computed tomography. J Rheumatol 1994; 21:2088-2095.
  pubmed

• 27) Bollow M, Braun J, Hamm B, et al. Early sacroiliitis in patients with spondyloarthropathy:evolution with dynamic gadolinium-enhanced MR imaging. Radiology 1995; 194:529-536.

• 28) Blum U, Buitrago-Tellez C, Mundinger A, et al. Magnetic resonance imaging (MRI) for detection of active sacroiliitis:a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol 1996; 23:2107-2115.
  pubmed

• 29) Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535-543.

• 30) Rudwaleit M, Feldtkeller E, Sieper J. Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside. Ann Rheum Dis 2006; 65:1251-1252.
  pubmed

• 31) 七川歡次, 辻本正記. 強直性脊椎炎:その早期診断, 頻度, 病囚について. リウマチ病II (七川歡次編集), 1973, p189216, 大阪, 永井書店.

• 32) 武仲義孝, 七川歡次, 廣田茂永. 脊椎炎の有病率について:三重県阿山町でのリウマチ病検診から. 第1回日本AS研究会プログラム抄録集, 1991, p18.

• 33) 井上康二, 川崎拓, 武仲義孝, 七川歡次. わが国におけるSpondylarthropathyの推定有病率. 第50回日本リウマチ学会総会学術集会プログラム抄録集, 2006, p215.

• 34) Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41:58-67.
  pubmed

• 35) Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France:2001. Ann Rheum Dis 2005; 64:1431-1435.
  pubmed

• 36) Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol 1999; 26:2622-2627.

• 37) Andrianakos A, Trontzas P, Christoyannis F, et al. Prevalence of rheumatic diseses in Greece:a crosssectional population based epidemiological study:the ESORDIG Study. J Rheumatol 2003; 30:1589-1601.

• 38) Bruges-Armas J, Lima C, Peixoto MJ, et al. Prevalence of spondyloarthritis in Terceira, Azores:a population based study. Ann Rheum Dis 2002; 61:551-553.
  pubmed

• 39) 長総義弘, 菊地臣一, 紺野慎一:. 腰痛, 下肢痛, 膝痛に関する疫学的検討. 整・災外 1994; 37:59-67.

• 40) Suka M, Yoshida K. Musculoskeletal pain in Japan:prevalence and interference with daily activities. Mod Rheumatol 2005; 15:41-47.

• 41) Yamaguchi A, Tsuchiya N, Mitsui H, et al. Association of HLA-B39 with HLA-B27 negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients:evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995; 38:1672-1677.
  pubmed

• 42) Tsujimoto M. Epidemiological research on the prevalence of ankylosing spondylitis. Med J Osaka Univ 1978; 28:363-381.
  pubmed

P.56 掲載の参考文献

• 1) Kellgren JH. Diagnostic criteria for population studies. Bull Rheum Dis 1962; 3:291-292.

• 2) Bennett PH, Wood PHN, Population studies of the rheumatic diseases. Amsterdam:Excerpta Medica 1968:457.

• 3) Wallance SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20:895-900.

• 4) 大島良雄. 痛風の臨床. 日内会誌1965; 54:291-310.

• 5) 小松原良雄, 七川歡次, 前田 晃, ら. 大阪地方における痛風症の現況. 中部整災誌 1967; 10:228-230.

• 6) 七川歡次, 痛風の疫学. 内科 MOOK 1983; 21:22-31.

• 7) Kato H, Duff IF, Russell WJ, et al. Rheumatoid arthritis and gout in Hiroshima and Nagasaki. J Chron Dis 1971; 23:659-679.

• 8) Nishioka K, Mikanagi K. Hereditary and environmental factors influencing on the serum uric acid throughout ten years population study in japan. Adv Exp Med Biol 1980; 22:55-159.

• 9) 西岡久寿樹, 御巫清允, 広瀬和彦. 痛風および高尿酸血症の臨床. リウマチ 1974; 14:95-105.

• 10) Akizuki S. A population study of hyperuricemia and gout in Japan;analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano prefecture. Rheumachi 1982; 22:201-208.
  pubmed

• 11) 塩 宏. 鳥取県における痛風の有病率. 高尿酸血症と痛風 1994; 2:113-115.

• 12) 藤森 新. 高尿酸血症・痛風の疫学と背景因子:高尿酸血症・痛風は増え続けているか. プリン・ピリミジン代謝 1997; 19:123-133.

• 13) 副島道正. 航空機乗員における痛風と高尿酸血症. 宇宙航空環境医学 1997; 34:43-45.

• 14) 石田宗治, 松田晴夫. 痛風および高尿酸血症に関する調査研究. 石川県衛生公害研究所年報 1987; 23:235-244.

• 15) 浅田恒夫, 高木靖弘, 松田 漸. 福井県における高尿酸血症等の疫学調査 (第1報) . 福井県衛生研究所調査研究報告 1985; 23:31-35.

• 16) 川崎 拓, 七川歡次. 住民検診による痛風の疫学調査. 痛風と核酸代謝 2006; 30:66.

• 17) Wallace KL, Wallace KL, Riedel AA, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31:1582-1587.

• 18) Adams PF, Hendershot GE, Marano MA. Centers for disease control and prevention/national center for health statistics. Current estimates from the National Health Interview Survey, 1996, Vital Health Stat 10. 1999; 200:1-203.
  pubmed

• 19) Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology:results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64:267-272.
  pubmed

• 20) Salaffi F, De Angelis R, Grassi W, et al. Prevalence of musculoskeletal conditions in an Italian population sample:results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23:819-828.

• 21) Dai SM, Han XH, Zhao DB, et al. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China:a COPCORD study. J Rheumatol 2003; 30:2090-2091.

• 22) Zimmet PZ, Whitehouse S, Jackson L, et al. High prevalence of hyperuricaemia and gout in an urbanised Micronesian population. Br Med J 1978; 13:1237-1239.

• 23) Chou CT, Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol 1998; 37:258-262.
  pubmed

• 24) 藤森 新, 伊藤 洋. 高尿酸血症 痛風-疫学の動向:高尿酸血症・痛風は増え続けているか. 高尿酸血症と痛風 2004; 12:114-119.

• 25) 山中 寿, 作山理子, 渡辺純子, ら. 女性, 若年者における痛風 最近の傾向. 高尿酸血症と痛風 1994; 2:23-29.

• 26) 七川歡次, 武仲善彦, 川田陽一, ら. 増加している高尿酸血症の背景. Medical Practice 1988; 5:380-381.

• 27) Choi HK, Atkinson K Karlson EW, et al. Alcohol intake and risk of incident gout in men:a prospective study. Lancet 2004; 363:1277-1281.

• 28) Choi HK Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-1103.

骨関節, 脊椎, 神経

P.64 掲載の参考文献

• 1) Kelly RB. Storage and relaese of neurotransmitters. Cell 1993; 72:43-53.

• 2) Bean AJ, Zhang X, Hoekefelt T. Peptide secretion:what do we know? FASEB J 1994; 8:630-634.

• 3) Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA splicing. Nature 1983; 304:129-135.

• 4) Wimalawansa SJ. Effects of neonatal capsaicin therapy on plasma contents and tissue levels of immunoreactive-CGRP. Peptide 1993;14:247-252.

• 5) Kruger L, Mantyh W, Sternini C, et al. Calcitonin gene-related peptide (CGRP) in the rat central nervous system:pattern of immunoreactivity and receptor binding sites. Brain Res 1988; 463:223-244.

• 6) Wimalawansa SJ, Emson PC, MacIntyre I. Regional distribution of calcitonin gene-related peptide and its specific binding sites in rats with panicular reference to the nervous system. Neuroendocrinology 1987; 46:131-136.

• 7) Steifert H, Sawchenko P, Chesnut J, et al. Receptor for calcitonin gene-related peptide:binding to exocrine pancreas mediates biological actions. Am J Physiol 1985; 249:G147-151.

• 8) Bjurholm A, Kreicbergs A Brodin E, et al. Substance P-and CGRP-immunoreactive nerves in bone. Peptide 1988; 9:165-171.
  pubmed

• 9) Crawford A, Evans DB, Sklodt ll. Effects of human calcitonin gene related peptide on human bone-derived cells in culture. Bone 1986; 7:157-158.

• 10) Kawase T, Burns DM. Calcitonin gene-related peptide stimulates potassium efflux through adenosine triphosphate-sensitive potassium channels and produces hyperpolarization in osteoblastic UMR-106 cells. Endocrinology 1998; 34:160-168.

• 11) Vigney A, McCarty TL. The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth by primary fetal rat osteoblasts. Bone; 1996. 18:331-335.

• 12) Sakagami Y, Girasole G., Yu, XP, et al. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinctive bone marrow-derived murine stromal cell lines. J Bone Miner Res 1993; 8:811-816.
  pubmed

• 13) Millet l, Vigney A. The neuropeptide calcitonin gene-related peptide inhibits tnf-alpha but poorly induces IL-6 production by fetal rat osteoblasts. Cytokine 1997; 9:999-1007.

• 14) Imai S, Tokunaga Y, Maeda, et al. CGRP-, SP-and TH-immunoreactive innervation of rat bone marrows. An immunohistochemical and ultrastructural investigation on possible efferent and afferent mechanisms. J Orthop Res 1997; 15:133-140.

• 15) Zaidi M, Chambers TJ, Gaines Das RE, et al. A direct action of human calcitonin gene related peptide on isolated osteoclasts. J Endocrinol 1987; 115:511-518.
  pubmed

• 16) Struthers AD, Brown MJ, Macdonald DW, et al. Human calcitonin gene related peptide:A potent endogenous vasodilatation in man. Clin Sci 1986; 70:389-393.
  pubmed

• 17) Imai S, Rauvala H, Konttinen YT, et al. Possible efferent targets of osseous CGRP-immunoreactive nerve fiber before and after bone destruction in adjuvant arthritic rat. An ultramorphological study on their terminal-target relations. J Bone Miner Res 1997; 12:1018-1027.

• 18) Imai S, Konttinen YT, Tokunaga Y, et al. Tyrosine hydroxylase immunoreactive nerve fibres in rat posterior longitudinal ligament. J Auton Nerv Syst 1997; 63:51-60.
  pubmed

• 19) Moore RE, Smith CK II, Bailey CS, et al. Characterization of beta-adrenaegic receptors on rat and huma osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23:301-315.

• 20) Bjurholm A, Kreicberg A, Schulzberg M, et al. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, ans Saos2) and primary bone cells. J Bone Miner Res 1992; 7:1011-1019.

• 21) Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-432.
  pubmed

• 22) Tartaglia LA, Dembski M, Weng X, et al:Identiflcation and expression cloning of a leptin receptor, 0B-R. Cell 1995; 83:1263-1271.

• 23) Ducy P, Anlling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay:a central control of bone mass. Cell 2000; 100:197-207.

• 24) Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111:305-317.
  pubmed

• 25) Allison SJ, Balock P, Sainsbury A, et al. Conditional deletion of hypothalamic Y2 receptor reverts gonadectomy-induced bone loss inadult mice. J Biol Chem 2006; 281:23436-23444.

P.70 掲載の参考文献

• 1) 杉尾嘉嗣. Marfan症候群. 小児内科 1998; 30:323-326.

• 2) Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005; 366:1965-1976.
  pubmed

• 3) Dietz HC. Marfan syndrome. 2005; http://www.genereviews.org/profiles/marfan/ (日本語訳:安藤孝志, 涌井敬子, 櫻井晃洋:http://grj.umin.jp/grj/marfan.htm)

• 4) De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996; 62:417-426.
  pubmed

• 5) Lopes KRM, Delezoide AL, Baumann C, et al. Prenatal Marfan syndrome:report of one case and review of the literature. Prenat Diagn 2006; 26:696-699.
  pubmed

• 6) Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006;43:769-787.
  pubmed

• 7) Lemaire R, Bayle J, Lafyatis R. Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-β regulation and systemic sclerosis. Curr Opin Rheumatol 2006; 18:582-587.

• 8) Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004; 36:855-860.
  pubmed

• 9) Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355:788-798.
  pubmed

• 10) Siracusa LD, McGrath R, Ma Q et al. A tandem duplication within the fibrillin 1 gene is associated with the mous tight skin mutation. Genome Res 1996; 6:300-313.

• 11) Falanga V, Jalien JM, Obseru atrions in the paternal role of transforming growth factor-beta in cutaneous fibrosis systemic sclerosis. Am NY Acad Sci 1990; 589:161-171.

• 12) Simkin AP. Acetabular osteitis in ankylosing spondylitits:Dose fiblin figuer in its pathogenesis? J Rheumatol 2001; 28:2663-2666.

• 13) Kiss C, Jonap I, Gergely P, et al. Coexistant Marfan's syndrome and ankyolsing spondylitis. J Rheumatol 2006; 33:1199-1200.

• 14) American Academy of Pediatrics Committee on Genetics. Health supervision for children with Marfan syndrome. Pediatrics 1996; 98:978-982.

• 15) Habashi JP, Judge DP, Holm TM, et al. Losartan, an ATI antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117-121.

P.81 掲載の参考文献

• 1) Miki K, Fukuoka T, Tokunaga A, et al. Calcitonin gene-related peptide increase in the rat spinal dorsal horn and dorsal column nucleus following peripheral nerve injury:Up-regulation in a subpopulation of primary afferent sensory neurons Neuroscience 1998; 468, 82:1243-1252.

• 2) McMahon SB, Bennett DLH. Trophic factor and pain. Textbook of pain, 4th ed, ed by. Wall PD & Melzack R, Churchill Livingstone, Edinburgh, 1999; p105-128.

• 3) Wall PD, Gutnick M. Ongoing activity in peripheral nerves:the physiology and pharmacology of impulses originating from a neuroma. Exp Neurolo 1974; 43:580-593.

• 4) Dougherty PM, Palecek J, Palaeckova Y, et al. The role of NMDA and non-NMDA excitatory amino acid receptor in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli. J Neurosci 1992; 12:3025-3041.

• 5) Headley PM, Parsons CG, West DC. The role of N-methylaspartate receptors in mediating responses of rat and cat spinal neurons to defined sensory stimuli. J Neurophysiol 1987; 385:169-188.

• 6) Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization independent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44:293-299.

• 7) Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep dorsal horn neurons following C-fiber stimulation. Neurophamlacology 1987; 26:1235-1238.
  pubmed

• 8) Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992; 355:7577.

• 9) Hokfelt T, Zhang X, Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci 1994; 17:22-30.
  pubmed

• 10) Noguchi K, Kawai Y, Fukuoka T, et al. Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons. The Journal of Neuroscience 1995; 15 (11):7633-7643.
  pubmed

• 11) Ushida T, Willis WD. Changes in dorsal hom neuronal responses in an experimental wrist contracturemodel. J Orthop Sci 2001; 6:4652.

• 12) Iadarola MJ, Max MB, Berman KF, et al. Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. Pain 1995; 63:55-64.
  pubmed

• 13) Ushida T, Ikemoto T, Taniguchi S, et al. Virtual pain stimulation of allodynia patients activates cortical representation of pain and emotions:a functional MRI study. Brain Topogr 2005; 18:27-35.
  pubmed

• 14) Kulkarni B, Bentley DE, Elliott R, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum 2007; 56:1345-1354.
  pubmed

• 15) 三木健司, 春日慎一, 赤堀 脩. CRPS type II (カウザルギー) に対する薬物治療. 日手会誌 2006; 第23巻:587-590.

• 16) 勝見泰和, 北條達也, 坂本敏浩, ら. 医療事故例による末梢神経損傷の検討. 日手会誌 2001; 18:168-172.

• 17) 近藤三鈴, 酒井雅人, 山鳥嘉世, ら. カルバマゼピン服用後中毒疹が生じた1症例. 第34回日本ペインクリニック学会関西地方会.

• 18) Kawamura M, Ohara H, Go K, et al. Neurotropin Induces Antinociceptive Effect by Enhancing Descending Pain Inhibitory Systems Involving 5-HT3 and Noradrenergic α2 Receptors in Spinal Dorsal Horn. Life Sciences 1998; 62:2181.

• 19) 今井 昇. 三叉神経痛の薬物治療. Quintessence 1999; 18:603-607.

• 20) Fromm GH. The pharmacology of trigeminal neuralgia. Clin Neuropharmacol 1989; 12:185-194.
  pubmed

• 21) 村崎光邦. Carbamazepine (Tegretol) . 臨床麻酔 1978; 2:813-816.

• 22) クロナゼパム製品基本情報 2005年10月改訂中外製薬.

• 23) Lankford LL. Reflex sympathetic dystrophy. Operative Hand Surgery (ed by Green DP), 2nd ed, Chrchill Livingstone 1988:633-663.

• 24) Kozin F. The reflex sympathetic dystrophy syndrome. Clinical and histologic studies; evidence for bilaterality, response to corticosteroids and articular involvement. Am J Med 1976; 60:321-331.
  pubmed

• 25) 井関一道, 古瀬洋一. CRPS(RSD)の治療-早期ステロイド療法とリハビリテーションの役割-. MB Orthop 2005; 18:15-21.

• 26) Inada Y, Morimoto S, Moroi K, et al. Surgical relief of causalgia with an artificial nerve guide tube:Successful surgical treatment of causalgia (Complex Regional Pain Syndrome Type II) by in situ tissue engineering with a polyglycolic acid-collagen tube. Pain 2005; 117:251-258.
  pubmed

• 27) 堺 慎, 大川 匡, 浅岡隆浩. 注射・採血に関わる神経損傷例と医療事故の検討. 第50回日本手の外科学会, 2007.

P.89 掲載の参考文献

• 1) Abe M, Ishizu T, Shirai H, et al. Tardy ulnar nerve palsy caused by cubitus varus deformity. J Hand Surg 1995; 20-A:5-9.
  pubmed

• 2) Buehler MJ, Thayer DT. The elbow flexion test. A clinical test for the cubital tunnel syndrome. Clin Orthop 1988; 233:213-216.

• 3) Novak CB, Lee GW, Mackinnon SE, et al. Provocative testing for cubital tunnel syndrome. J Hand Surg 1994; 19-A:817-820.

• 4) Okamoto M, Abe M, Shirai H, et al. Morphology and dynamics of the ulnar nerve in the cubital tunnel. J Hand Surg 2000; 25-B:85-89.

• 5) Okamoto M, Abe M, Shirai H, et al. Diagnostic ultrasonography of the ulnar nerve in cubital tunnel syndrome. J Hand Surg 2000; 25-B:499-502.

• 6) 渡辺千聡, 阿部宗昭, 白井久也, ら. 肘部管症候群における尺骨神経の断面積, 超音波検査による検討. 日肘会誌 2006;13:3-4.

• 7) 石津恒彦, 阿部宗昭, 土居宗算, ら. 肘部管症候群の術後成績. 日手会誌 1993;10:398-401.

• 8) 渡辺千聡, 阿部宗昭, 白井久也, ら. 肘部管症候群における尺骨神経皮下前方移動術の成績. 日手会誌 2002; 19:749-751.

• 9) 渡辺千聡, 阿部宗昭, 白井久也, ら. 肘部管症候群における尺骨神経皮下前方移動術の成績 (第2報) . 日肘会誌 2005; 12:33-34.

P.100 掲載の参考文献

• 1) 厚生統計協会編集. 第4章 健康状態と受療状況. 厚生の指標臨時増刊号 (国民衛生の動向) 2007; 54:71-77, 428, 492.

• 2) Mixter WL, Barr JS. Rupture of the intervertebral disc with involvement of spinal canal. New Engl J Med 1934; 211:210-215.

• 3) 西林保朗. 腰痛の慢性化とその予防-線維化と線溶系異常を中心に-リウマチ病セミナーVIII (七川歓次監 修), p120-133, 大阪, 永井書店, 1997.

• 4) 西林保朗, 七川歡次, 福田眞輔ら. 根性腰痛症とEnthesopathy-椎間板ヘルニアにおけるEnthesisの電顕観察-日整会誌 1981; 55:1344-1345.

• 5) 七川歓次, 武中善孝, 西林保朗. 腰痛症-enthsopathy-関節外科 1990; 9:273-279.

• 6) Langenskiold A, Valle M. Epidurally placed free fat grafts visualized by CT scanning 15-18 years after discectomy. Spine 1985; 10:97-98.
  pubmed

• 7) Kawakami M, Weinstein JN, Tamaki T, et al. The difference in nociceptive potential of the nucleus pulposus and the annulus fibrosus. In Low back pain:a scientific and clinical overview (Weinstein JN, Gordon SL Ed), p209-213, Illinois, American Academy of Orthopaedic Surgeons, 1996.

• 8) Glonblad M, Varri J, Tolonen J, et al. A controlled immunohistochemical study of inflammatory cells in disc hemiation tissue. Spine 1994; 19:2744-2751.

• 9) Woertgen C, Rothoerl RD, Brawanski A Influence of macrophage infiltration of herniated lumbar disc tissue on outcome after lumbar disc surgery. Spine 2000; 25:871-875.
  pubmed

• 10) Habtemariam A, Gronblad M, Virri L, et al. A comparative immunohistochemical study of inflammatory cell in acute stage and chronic stage disc herniations. Spine 1998; 20:2159-2166.

• 11) Gertzbein SD, Tile M, Gross A, et al. Autoimmunity in degenerative disc disease of the lumbar spine. Ortop Clin North Am 1975; 6:67-74.

• 12) Saal JS. The role of inflammation in lumbar pain. Spine 1995; 20:1821-1823.

• 13) 福田眞輔. 腰痛と生物活性物質. リウマチ病セミナーVII (七川歡次監修), p99-105, 大阪, 永井書店, 1996.

• 14) Weinstein JN, Gordon SL. Low back pain:a scientific and clinical overview. Illinois, American Academy of Orthopaedic Surgeons, 1996.

• 15) DeLeo JA, Colburn RW. The role of cytokines in nociception and chronic pain. In Low back pain:a scientific and clinical overview (Weinstein JN, Gordon SL Ed), p163-185, Illinois, American Academy of Orthopaedic Surgeons, 1996.

• 16) Kang JD, Evans CH. Cytokines, nitric oxide, prostaglandin E2, and idiopathic Iow back pain. In Low back pain:ascientific and clinical overview (Weinstein JN, Gordon SL Ed), p529-538, Illinois, American Academy of Orthopaedic Surgeons, 1996.

• 17) Mulleman D, Mammou S, Griffoul I, et al. Pathophysiology of disk-related sciatica. 1.-evidence supporting a chemical component. Joint Bone Spine 2006;73:151-158.

• 18) Cooper RG, Freemont AJ. TNF-α blockade for hemiated intervertebral disc-induced sciatica:away forward st last? Rheumatology 2004;43:119-121.

• 19) Mulleman D, Mammou S, Griffoul I, et al. Pathophysiology of disk-related low back pain and sciatica. H. Evidence supporting treatment with TNF-alpha antagonists. Joint Bone Spine 2006;73:270-277.

• 20) Goupille P, Mulleman D, Valat J-P. Radiculopathy associated with disc herniation. Ann Rheum Dis 2006;65:141-143.
  pubmed

• 21) Karppinen J, Korhonen T, Malmivaara A, et al. Tumor necrosis factor-a monoclonal antibody, Infliximab, used to manage severe sciatica. Spine 2003;28:750-754.
  pubmed

• 22) Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc herniation-induced sciatica with infliximab:results of a randomized, controlled, 3-month follow-up study. Spine 2005;30:2724-2728.
  pubmed

• 23) Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc-herniation-induced sciatica with infliximab:one-year follow-up results of FIRST II, a randomized controlled trial. Spine 2006;31:272759-2766.

• 24) 西林保朗, 小形晶子. 筋筋膜痛症候群. リウマチ病セミナーXVII(七川歡次監修), p101-113, 大阪, 永井書店, 2006.

• 25) ロバート・L・スウェジー (七川歓次監訳) . 腰痛-その治療と予防法 (GOOD NEWS FOR BAD BACKS), 東京, ティービーエス・ブリタニカ, 1996.

• 26) 菊地臣一. 続・腰痛をめぐる常識のウソ. 東京, 金原出版, 1998.

• 27) 菊地臣一. 腰痛. 東京, 医学書院, 2003.

• 28) Adams N. The psychophysiology of low back pain. New York, Churchill Livingstone, 1997.

• 29) 細井昌子. 慢性疼痛の認知行動療法-痛み認知と痛み行動へのアプローチー リウマチ病セミナーXVII (七川歡次監修), p181-188, 大阪, 永井書店, 2006.

• 30) 宮本省三, 沖田一彦編集. 認知運動療法入門. 東京, 協同医書出版社, 2002.

P.116 掲載の参考文献

• 1) 七川歡次. Fibroblastic rheumatism (線維芽細胞性リウマチ) とリウマチ病でのfibrosis. リウマチ病セミナーV (七川歡次監修), 1994, 58-65, 大阪, 永井書店.

• 2) Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006;367:241-251.
  pubmed

• 3) Mitchinson MJ. Chronic periaortitis and periarteritis. Histopathology 1984;8:589-600.
  pubmed

• 4) Parums DV. The spectrum of chronic periaortitis. Histopathology 1990;16:423-431.
  pubmed

• 5) Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxddized low-density lipoproteins and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990;114:383-387.
  pubmed

• 6) Parums DV, Chadwick DR, Mitchinson MJ. The localisation of immunoglobulin in chronic periaortitis. Atherosclerosis 1986;61:117-123.
  pubmed

• 7) Mitchinson MJ. Insoluble lipids in human atherosclerotic plaques. Atherosclerosis 1982;45:11-15.
  pubmed

• 8) Klein J, Sato A.:The HLA system:second of two parts. N Engl J Med 2000;343:782-786.
  pubmed

• 9) Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002;359:1403-1404.
  pubmed

• 10) Zen, Y, Sawazaki, A, Miyayama, S, et al. A Case of retroperitoneal and mediastinal fibrosis exhibiting elevated levels of IgG4 in the absence of sclerosing pancreatitis (autoimmune pancreatitis). Hum Pathol 2006;37:239-243.
  pubmed

• 11) Thomas MH, Chisholm GD. Retroperitoneal fibrosis associated with malignant disease. Br J Cancer;28:453-458.
  pubmed

• 12) Chander S, Ergun EL, Chugani HT, et al. High 2-deoxy-2-[18F]-fiuoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor. Mol Imaging Biol 2002;4:363-368.

• 13) Graham JR, Suby HI, LeCompte PR, et al. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966;274:359.
  pubmed

• 14) Utz, DC, Rooke, ED, Spitell, JA Jr, Bartholomew, LG.:Retroperitoneal fibrosis in patients taking methysergide. JAMA 191:983, 1965.

• 15) Okada H, Takahira S, Sugahara S, et al. Retroperitoneal fibrosis and systemic lupus erythematosus. Nephrol Dial Transplant 1999;14:1300-1302.
  pubmed

• 16) Leblanc CM, Inman RD, Dent P, et al. Retroperitonealfibrosis:an extra-articular manifestation of ankylosing spondylitis. Arthritis Rheum 2002;47:10-214.

• 17) Tsai T-C, Chang P-Y, Chen B-F, et al. Retroperitoneal fibrosis and juvenile rheumatoid arthritis. Pediatr Nephrol 1996;10:208-209.
  pubmed

• 18) Wilson MC, Beny AR, McNair TJ, et al. Obstructive uropathy after pan-proctocolectomy for ulcerative colitis, Gut さ1992;21:80-809.

• 19) Moul JW. Retroperitoneal fibrosis following radiotherapy for stage I testicular seminoma. J Urol 1992;147:124-126.

• 20) Witten, DM. Retroperitoneal fibrosis. In:Clinical Urography, Pollack, HM (Ed), WB Saunders, Philadelphia, 1990, p. 2469.

• 21) Demko, TM, Diamond, JR, Groff, J. Obstructive nephropathy as a result of retroperitoneal fibrosis:A review of its pathogenesis and associations. J Am Soc Nephrol 1997;8:684.
  pubmed

• 22) Fagan, CJ, Larrieu, AJ, Amparo, EG. Retroperitoneal fibrosis:ultrasound and CT features. AJR Am J Roentgenol 1979;133:239.
  pubmed

• 23) Feinstein, RS, Gatewood, OMB, Goldman, SM, et al. Computed tomography in the diagnosis of retroperitoneal fibrosis. J Urol 1981;126:255.

• 24) Arrive L, Hricak H, Tavares NJ, et al. Malignant versus nonmalignant retroperitoneal fibrosis:differentiation with MR inlaging. Radiology 1989;172:139-143.
  pubmed

• 25) Kardar AH, Kattan S, Lindstedt E, et al:Steroid therapy for idiopathic retroperitoneal fibrosis:dose and duration. J Urol 2002;168:550-555.
  pubmed

• 26) Loffeld RJLF, van Weel TF. Tamoxifen for retroperitoneal fibrosis. Lancet 1993;341:382.

• 27) Al-Musawi D, Mitchenere P, Al-Akraa M:Idiopathic retroperitoneal fibrosis treated with tamoxifen only. Br J Urol 1998;82:442-443.
  pubmed

• 28) .Bouroma R, Chevet D, Michel F, et al. Treatment of idiopathic retroperitoneal fibrosis with tamoxifen only. Nephrol Dial Transplant 1997;12:2407-2410.

• 29) Wamatz K, Keskin AG, Uhl C, et al. Immunosuppressive treatment of chronic periaortitis:a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005;64:828-833.

• 30) Hellstrom HR, Perez-Stable EC. Retroperitoneal fibrosis with disseminated vasculitis and intrahepatic sclerosing cholangitis. Am J Med 1966;40:184-187.

• 31) Dehner LP, Cothn CM. Idiopathic fibrosclerotic disorders and other inflammatory pseudotumors. Semin Diagn Pathol 1998;15:161-173.

P.121 掲載の参考文献

• 1) 西岡宗徳, 木本 実, 油谷浩之, ら. 大学アメリカンフットボール選手における膝伸・屈筋柔軟性の意義. スポーツ傷害2000;5:29-30.

• 2) Hartig DE, Henderson JM. Increasing flexibility decreases lower extremity overuse injuries in military basic trainees. Am J Sports Med 1999;27:173-176.
  pubmed

• 3) Heidt RS Jr, Sweeterman LM, Carlonas RL, et al. Avoidance of soccer injuries with preseason conditioning. Am J Sports Med 2000;28:659-662.
  pubmed

• 4) Hewett TE, Lindenfeld TN, Riccobene JV, et al. The effect of neuromuscular training on the incidence of knee injury in female athletes. A prospective study. Am J Sports med 1999;27:699-706.
  pubmed

• 5) 坂井宏成, 野出光昭, 黒坂昌弘, ら. 半月板単独損傷に対する関節鏡視下半月板部分切除術後のスポーツ復帰 とくにスポーツ活動レベルの高い症例について. 日本整形外科スポーツ医学会雑誌2001;21:133-137.

• 6) Ahmed AM, Burke DL In-vitro measurement of static pressure distribution in synovial joints-Part I:Tibial surface of the knee. J Biomech Eng 1983;105:216-225.
  pubmed

• 7) Kobayashi Y, Kimura M, Higuchi H, et al. Juxta-articular bone marrow signal changes on magnetic resonance imaging following arthroscopic meniscectomy. Arthroscopy 2002;18:238-245.
  pubmed

P.127 掲載の参考文献

• 1) 四宮謙一. 上腕骨外側上穎炎診療ガイドライン, 東京, 南江堂;2006:p15-20.

• 2) 福田眞輔. テニスによるスポーツ障害. リウマチ病セミナー (七川歡次監修) XVII, 大阪, 永井書店; 2006;p114-123.

• 3) 稲垣三郎, 船越正男, 薄井正道, ら. Intersection syndromeの治療経験. 北海道整形災害外科学学会2005; 47:1-2.

• 4) 町野 哲, 澤村大輔, 乃村俊史, ら. Intersection Syndromeの1例. 皮膚臨床2004;46:1248-1249.

• 5) Grundberg AB, Reagan DS. Pathologic anatomy of the foreaml:intersection syndrome. J Hand Surg 1985; 10:299-302.
  pubmed

• 6) 麻生邦一, 多田勝弘, 鳥巣岳彦, ら. Intersection syndromeの病態について. 日手会誌1996;13:186-188.

• 7) Fiolle J. Le"carpe bossu". Bull Mem Soc Nat Chir 1931;57:1687-1690.

• 8) 杉本義久, 藤田亮介. ゴルフスイングで疼痛を生じたcarpal bossの1例. 整形外科2002;53:1175-1177.

• 9) Cuono CB, Waston HK:The carpal boss;surgical treatment and etiological considerations. Plast Reconstr Surg 1979;63:88-93.

• 10) Clayton ML, Ferlic DC. The wrist in rheumatoid arthritis. Clin. Orthop 1975;106:192-197.
  pubmed

燐・カルシウム代謝

P.137 掲載の参考文献

• 1) Duncan H, Frost HM, Villanueva AR, et al. The osteoporosis of rheumatoid arthritis. Arthritis Rheum 1965; 8:943-954.
  pubmed

• 2) 上好昭孝. リウマチにおける性ホルモン, 骨代謝マーカーと骨. CLINICAL CALCIUM 1993;3:42-48.

• 3) Hooyman JR, Mclton U, Nelson AM, et al. Fractures after rheumatoid arthritis. Arthritis and Rheumatism 1984;27:1351-1361.

• 4) Clowes JA, Peel N, Eastell R. Glucocorticoid-induced osteoporosis. Cure Opin Rheumatol 2001;13:326-332.

• 5) Nawata I, Soen S, Takayanagi R, et al. Guideline on the management and treatment of glucocorticoid-induced osteoporosis of The Japanese Society for Bone and Mineral Research (2004 edition) . J Bone Miner Metab 2005;23:105-109.

• 6) NIH Consensus Devlopment Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.

• 7) American College of Rheumatology Task Force on Osteoporosis Guidline. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-1801.

• 8) 高柳涼一. ステロイド骨粗鬆症のマネジメント (田中良哉編), 東京, 医薬ジャーナル社, 2005;pp16-23.

• 9) 田中侑子, 大島久二. ステロイド性骨粗鬆症の診断と治療に関する縦断研究:診断・治療指針への予備的検討. Osteoporosis Jpn 2003;11:11-14.

• 10) 宗園 聡. わが国のステロイド性骨粗鬆症のガイドラインと解説.骨粗鬆症治療2006;5:31-35.

• 11) Adachi JD, Bensen WG, Brown J, et al. Intermittent etidoronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-387.

• 12) Sato S, Oosone Y, Suwa A et al. Effect of intermittent cyclical etidoronate therapyon corticosteroid induced osteoporosis in Japanese patients with connective tissue disease:3 year followup. J Rheumatol 2003;30:2673-2679.

• 13) 田中良哉, 岡田洋右. ステロイド性骨粗鬆症の病態. 骨粗鬆症治療2006;5:16-21.

• 14) 大中佳三, 高橋涼一. ステロイド性骨粗鬆症の発症メカニズム. 綜合臨牀 2006;54:2810-2820.

• 15) Chang DJ, Ji C, Kim KK, et al. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFaI on bone cells by glucocorticoid. J Biol Chem 1998;273:4892-4896.

• 16) Hofbauer LC, Gori J, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of gluticocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-4389.

• 17) Weinstein RS, Chen J, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-1048.
  pubmed

• 18) Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and romotion of apoptosis of osteoblasts and osteocytes by glucoconicoids. J Clin Invest 1998;102:274-282.

• 19) Harmus AR, Smails AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing:s syndrome. J Clin Endocrinol Metab 1995;80:2859-2865.

• 20) 骨粗鬆症診療における骨代謝マーカーの適正使用に関する検討委員会. 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2004年度版), Osteoporosis Jpn 2004;12:191-204.

• 21) Ton FN, Gunawardene SC, Lee H, et al. Effects of Low-Dose Prednisone on Bone Metabolism. J Bone Miner Res 2005;20:464-470.

• 22) van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis:a meta-analysis. Osteoporosis Int 2002;13:777-787.
  pubmed

• 23) van Staa TP, Leufkens HG, Abenhaim L, et al, Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
  pubmed

• 24) Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in post-menopausal patients with rheumatoid arthritis:Effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-857.

• 25) Sambrook PN, Eisman JA Yeates MG, et al. Osteoporosis in rheumatoid arthritis:Safety of low dose corticosteroids. Ann Rheum Dis 1986;45:950-953.
  pubmed

• 26) 平成14年度厚生労働省「免疫アレルギー疾患予防治療研究」-関節リウマチ・骨粗鬆症患者の疫学, 病態解明と治療法開発に関する研究から.

• 27) 平成16年度厚生労働省「免疫アレルギー疾患予防治療研究」から-関節リウマチ 骨粗鬆患者の疫学, 病態解明と治療法開発に関する研究から.

• 28) Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003;32:135-157.
  pubmed

• 29) 田中郁子, 大島被久二. ステロイド性骨粗鬆症の診断と治療に関する縦断研究. Osteoporosis Jpn 2003;11:11-14. 137

P.142 掲載の参考文献

• 1) 厚生労働省難治性疾患克服研究事業. 特発大腿骨頭壊死症の診断・治療に関するガイドライン 平成15年度, 骨関節系調査研究班特発性大腿骨頭壊死症調査研究分科会.

• 2) Aranow C, Zelicof S, Leslie D, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumato11997;24:2318-2322.
  pubmed

• 3) Sakamoto M, Shimizu K Iida S, et al. Osteonecrosis of the femoral head:aprospective study with MRI. J Bone Joint Surg Br 1997;79:213-219.

• 4) Takao M, Sugano N, Nishii T, et al. Longitudinal quantitative evaluation of lesion size change in femoral head osteonecrosis using three-dimensional magnetic resonance imaging and image registration. J Orthop Res 2006;24:1231-1239.
  pubmed

• 5) Sugano N, Nishii T, Shibuya T, et al. Contralateral hip in patients with unilateral nontraumatic osteonecrosis of the femoral head. Clin Orthop Relat Res 1997;334:85-90.
  pubmed

• 6) Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate:arandomized, placebo-controlled trial. Am J Med 1996;101:341-348.

• 7) Lane JM, Khan SN, O'Connor WJ, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 2001 ;382:6-12.
  pubmed

• 8) Millett PJ, Allen MJ, Bostrom MP. Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg Am 2002;84:236-249.

• 9) Astrand J, Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 2002;3:19.

• 10) Little D G, Peat RA, Mcevoy A, et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003;18:2016-2022.
  pubmed

• 11) Glimcher MJ, Kenzora JE. The biology of osteonecrosis of the human femoral head and its clinical implications:H. The pathological changes in the femoral head as an organ and in the hip joint. Clin Orthop Relat Res 1979;139:283-312.

• 12) Nishii T, Sugano N, Miki H, et al. Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 2006;443:273-279.
  pubmed

• 13) Agarwala S, Jain D, Joshi VR, et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology 2005;44:352-359.
  pubmed

• 14) Lai KA, Shen WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005;87:2155-2159.
  pubmed

検査法

P.150 掲載の参考文献

• 1) Steinbrocker O, Traeger CH, Battman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-665.

• 2) Kellgren JH, Bier F. Radiological sign in rheumatoid arthritis. Ann Rheum Dis 1956;15:1555-1560.

• 3) Berns DL, Lin RK. Roentgen diagnosis of rheumatoid arthritis. 1969, Springfield, ILCC Thomas.

• 4) Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrist shoud be included in a score of radiologlc abnormalities used to assess rheumatoid arthritis. Arthritis Rheum 1985;28:1326-1335.

• 5) Sharp JT, Lipsky MD, Collins LC. Methods of scoring the progression of radiologic changes in rheumatoid arthritis:correction of radiologic, clinical and laboratory abnormalities. Arthritis Rheurn 1971;14:706-720.

• 6) Larsen A, Dale K, Fek M. Radiographic evaluation of rheumatoid arthritis and related condition by standard reference films. Acta Radiol 1971;18:481-491.

• 7) Trenntham DE, Masi AT, Eek K Carpo-metacarpal ratio:A new quantitative measure of radiologic progression of wrist involvement in rheumatoid arthritis. Arthritis Rheum 1976;19:939-944.

• 8) van der Heijde A, Remme CA, Hoffman DM, et al. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1486-1475.

• 9) Genant HK, Jiang Y, Peterfy C, et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1683-1690.

• 10) Scott DI, Houssion DA, Lassonen L. Proposed modification to Larsen's scoring methods for hand and wrist radiogrophs. Brit J Rheumatol 1995;34:56.

• 11) Rau R, Herbom G. A modified version of Larsenis scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol 1995;22:1976-1982.

• 12) Boini S, Gullemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis:properties and advantage. Ann Rheum Dis 2001;690:817-827.

• 13) Guillemin F, Billot L, Boini S, et al. Reproducibiltiy and sensitivity to change of 5 methods for scoring hand radiographic damage in patients with rheumatoid arthritis. J Rheumatol 2005;32:778-786.

• 14) Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde, and Larsen/Scott scoring methods by clincal experts and comparison with the smallest detectable difference. Arthritis Rhema 2003;46:913-920.

• 15) Bruynesteyn K, van der Heijde, Boers K, et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts:Influence of reading with or without known sequence. J Rheumatol 2002;29:12306-12312.

• 16) van der Heijde D, Simon L, Smolen L, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis:guidelines from a roundtable disussion. Arthritis Rheum 2002;47:215-218.

• 17) Welsing PMJ, Landewe RBM, van Riel PLCM, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis:A longitudinal analysis. Arhritis Rheum 2004;50:2082-2093.

• 18) 前田 晃. 慢性関節リウマチのX線額的評価法. リウマチ病セミナーX (七川歡次監修), 1998:143-151, 大阪, 永井書店.

• 19) 村田紀和. 滑膜炎のMRI. リウマチ病セミナーX (七川歡次監修), 1998:113-116, 大阪, 永井書店.

• 20) Peterfly CG. Magnetic resonance imaging of rheumatoid arthritis:The evolution of clinical applications through clinical trials. Semin Arthritis Rheum 2001;30:375-396.

• 21) McQueen FM, Benton N, Crabbe J, et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001;60:859-868.
  pubmed

• 22) McQueen FM, Benton N, Perry D, et al. Bone edema scored on magnetic resonsnce imaging scans of the dominamt carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1814-1827.

• 23) Ostergaard M, Hansen M, Stoltenberg M, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detecable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 2003;48:2128-2131.

• 24) Goldbach-Mansky R, Woodburn J, Tan L, et al. Magnetic resonance imaging in the evaluation for rheumatoid arthritis:a more precise image or just a more expensive one? Arthritis Reum 2003;48;585-599.

• 25) Ostergaard M, Conaghan P. Preface. Ann Rheum Dis 2006;13 (Suppl):i2.

• 26) Ostergaard M, Edmond J, MacQueen F, et al. An introduction to the EUIJAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2006;64 (Suppl):i3-i7.

• 27) Bird P, Conaghan P, Ejbjerg B, et al. The development of the EULAR-OMERACr rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2006;64 (Suppl):i8-i10.

• 28) Conaghan B, Bird P, Ejbjerg B, et al. The EULAR-OMERACT rheumatoid arthritis MRI image atlas:the metacarpophalangeal joints. Ann Rheum Dis 2006;64 (Suppl):i11-i22.

• 29) Ejbjerg B, McQeen F, Lassere M, et al. The EULAR-OMERACT rhematoid arthritis MRI reference image atlas:the wirst joint. Ann Rheum Dis 2005;64 (Suppl):i23-i47.

• 30) McQueen F, Lassere M, Bird P, et al. Pitfalls in scoring MR images of rheumatoid arthritis wrist and metacarpophalangeal joints. Ann Rheum Dis 2006;64:i (stlppl)-i48-i56.

• 31) Bird P, Lassere M, Shnier R, et al. Computerized measurement of magnetic resonance imaging erosion volumes in patients with rheumatoid arthritis:acomparison with existing magnetic resonance imaging scoring system and standard clinical outcome measures. Arthrtis Rheum 2003;48:614-624.

• 32) Report of American College of Rheumatology Extremity Magnetic Resonance Imaging Task Work. Extremity Magnetic Resonance Imaging in rheumatoid arthritis. Arthritis Rheum 2005;52:733-743.

• 33) Yosioka H, Itou S, Handa, et al. Low field compact magnetic resonance imaging system for the hand and wrist in rheumatoid arthritis. J Magn Reson Med 2006;23:370-376.

• 34) Itou S, Tuboi H, Sugihara M, et al. Inflimaxib使用患者の手足X線所見の変化に関する検討. Jpn J Rheum. Joint surg 2006;15:347.

• 35) Haavardsholm E, Ostergaard M, Ejbjerg B, et al. Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetc resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 2006;52:3860-3867.

• 36) Szkudlarek M, Court-Payen M, Jacobson S, et al. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 2003;48:955-962.

• 37) Terslev L, Torp-Pederson S, Samik A, et al. Doppler-ultrasound and magnetic resonance imaging of synoivial inflammation of the hand in rheumatoid arthritis. Arthritis Rheum 2003;48:2434-2441.

• 38) Ostergaard M, Wiell C. Ultrasonography in rheumatoid arthritis:a very promising method still needing more validation. Current Opin Rheumatol 2004;16:223-230.

• 39) Sheel AK, Hermann KA, Kahler E, et al. A novel Ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum 2005;52:733-743.

• 40) Sheel AK, Schmidt WA, Hermann A, et al. Interobserver reliability of rheumatogists performing musculoskeletal ultrasonography:results from a EULAR"Train the trainers"course. Ann Rheum Dis 2006;64:1043-1049.

• 41) Brow AK, O'connor Pj, Roberts, et al. Ultrasonography for rheumatologists:the developement of specific competency based educational outcomes. Ann Rheum Dis 2006;65:629-636.

• 42) Naredo E, Moller I, Moragues C, et al. Interobserver reliabilty in musculoskeletal ultrasonography:results from a"teach the teachers"RHEUMATOLOGIST course. Ann Rheum Dis 2006;66:14-19.

• 43) Wakefield J, Gipson WW, Conagham PG, et al. The value of sonography in the detection of bone erosion in the patiens with rheumatoid arthritis:Arthritis Rheum 2000;43:2762-2770.

• 44) Szkudlark M, Klarlund M, Narvestad E, et al. Ultrasonography of the metacarpophalangeal joints in rheumatoid arthritis:acomparison with magnetic resonance imaging, conventional radiography and clinical examination Arthritis Research & Therap 2006;8:1-11.

• 45) Backhaus M, Kamrady T, Sandrock D, et al. Arthritis of the fingers:A comprehensive approch compairing conventional radiography, sinchigraphy, ultrasound, and contrast-enhenced magnetic resonance imaging. Arthritis Rheum 1999;62:1232-1245.

• 46) Finckh A, Pablo P, Katz JN, et al. Performance of an automated computer-based scoring method to assess joint space narrowing in rheumatoid arthritis. Arthritis Rheum 2006;54:1444-1450.
  pubmed

• 47) Angwin J, Heald G, Lioyd, et al. Reliability and sensitivity of joint space measurement in hand radiographs using computerized image. J Rheumatol 2001;28:1825-1836.

• 48) Jawaid WB, Crosbie D, Shotton J, et al. Using digital Xray radiogrammetry in the assessment of joint damage in rheumatoid arthritis.. Ann Rheum Dis 2006;65:459-464.

• 49) Sheel AK, Krause A, Rheinbaben IM, et al:Assessment of proximal finger joint inflammation in patients with rheumatoid arthritis, using novel laser-based imaging technique, Arhritis Rheum 2002;46:1177-1184.

生物学的反応

P.157 掲載の参考文献

• 1) Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+T cells. Immunol Rev 2006;211:81-92.
  pubmed

• 2) Gately MK, Wolitzky AG, Quinn PM, et al. Regulation of human cytolytic lymphocyte responses by IL-12. Cell Immunol 1992;143:127-142.
  pubmed

• 3) Trinchieri G. Interleukin-12:acytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243.

• 4) Curtsinger JM, Valenzuela JO, Agarwal P, et al. Type I interferons provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174:4465-4469.
  pubmed

• 5) Curtsinger JM, Lins DC, Johnson CM, et al. Signal 3 tolerant CD8 T cells degranurate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol 2005;175:4392-4399.
  pubmed

• 6) Nguyen KB, Watford WO, Salomon R, et al. Critical role for STAT4 activation by type l interferons in the interferon-gamma response to viral infection. Science 2002;297:2063-2066.

• 7) Tham EL, Mescher MF. Signaling alterations in activation-induced non-responsive (AINR) CD8 T cells. J Immunol 2001;167:2040-2048.
  pubmed

• 8) Otten G, Germain R. Split anergy in a CD8+T cell:receptor-dependent cytolysis in the absence of interleukin-2 production. Science 1991;251:1228-1231.

• 9) Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell diferentiation. Cell 2002;111:837-851.

• 10) Shrikant P, Mescher MF. Opposing effects of promoting CD8 T cell growth and inducing apoptosis. J Immunol 2002 ;169:1753-1759.
  pubmed

• 11) Croft M. Co-stimulatory members of the TNFR family:keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-620.
  pubmed

• 12) Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2004;23:23-68.

• 13) Bansal-Pakala P, Halteman BS, Cheng MHY, et al. Costimulation of CD8 T cell responses by OX40. J Immunol 2004;172:4821-4825.
  pubmed

• 14) Bertram EM, lau P, Watt TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation:4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002;168:3777-3785.

• 15) Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991;353:858-861.

• 16) Lenardo M, Chan KM, Homung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Ann Rev Immunol 1999;17:221-253.

• 17) Wherry EJ, Barber DL, Kaech SM, et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 2004;101:16004-16009.

• 18) Welsh RM. Assessing CD8 T cell number and dysfunction in the presence of antigen. J Exp Med 2001;193:19F-22.

• 19) Wherry EJ, Blattman JN, Murali-Krishna K, et al. Viral persistence alters CD8 T cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77:4911-4927.
  pubmed

• 20) Schluns KS, Lefrancois L. Cytokine control of memory T cell development and survival. Nat Rev Immunol 2003 ;3:269-279.
  pubmed

• 21) Sun JC, Williams MA. Bevan MJ. CD4+T cells are required for the maintenance, not programming, of memory CD8+T cell response. Nat Rev Immunol 2004;4:595-602.

• 22) Schmidt CS, Mescher MF. Peptide Ag priming of na ive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12, J Immunol 2002;168:5521-5529.

P.167 掲載の参考文献

• 1) Ishii M, Iwai K, Koike M, et al. RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J Bone Miner Res 2006;21:965-976.
  pubmed

• 2) Miyado K, Yamada G, Yamada S, et al. Requirement of CDg on the egg plasma membrane for fertilization. Science 2000;287:321-324.

• 3) Willett B, Hosie M, Shaw A, et al. Inhibition of feline immunodeficiency virus infection by CD9 antibody operates after virus entry and is independent of virus tropism.J Gen Virol 1997;78:611-618.
  pubmed

• 4) Tachibana I, Hemler ME. Role of TM4SF proteins CD9 and CD81 in muscle cell fusion and myocytube maintenance. J Cell Bio 1999;146:893-904.

• 5) Takeda Y, Tachibana I, Miyado K, et al. CD9 and CD81 function to prevent the fusion of mononuclear phagocytes. J Cell Bio 2003;161:945-956.

• 6) Yi T, Kim HJ, Cho JY, et al. Tetraspanin CDg regulates osteoclastogenesis via regulation of p44/42 MAPK activity. Biochem Biophys Res Commun 2006;347:178-184.

• 7) Gupta N, DeFranco AL. Visualizing lipid raft dynamics and early signaling events during antigen receptormediated B-lymphocyte activation. Mol Bio Cell 2003;14:432-444.

• 8) Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202:345-351.
  pubmed

P.176 掲載の参考文献

• 1) Folkman J:Angiogenesis-dependent diseases. Semin Oncol 2001;28:536-542.
  pubmed

• 2) Zetter BR:Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-424.
  pubmed

• 3) Tachibana K, Kishimoto T, Nagasawa T, et al:The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Science 1998;393:591-594.

• 4) O' Reilly MS, Holmgren L, Folkman J, et al. Angiostatin. anovel angiogengeis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.

• 5) O' Reilly MS, Holmgren L, Folkman J, et al:Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
  pubmed

• 6) Gately S, Dhanabal M, Weichselbaum RR, et al:Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998;394:287-291.

• 7) O' Reilly MS, Boehm T, Folkman J, et al:Endostatin:an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
  pubmed

• 8) Boehm T, Folkman J, Browder T, O' Reilly MS:Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1998;390:404-407.
  pubmed

• 9) O'Reilly MS, Pirie-Shepherd S, Folkman J, et al:Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-1928.
  pubmed

• 10) Staudacher DL, Preis M, Flugelman MY, et al:Cellular and molecular therapeutic modalities for arterial obstructive syndrornes. Pharmacol Ther 2006;109:17-30.

• 11) Hurvitz H, Fehrenbacher L, Novotny W, et al:Bevacizumab plus irinotecan, nuorouracil and leukovorin foe metastatic colorectal cancer. N Eng J Med 2004;350:2335-2342.

• 12) Rosenfeld FJ, Brown DM, Kim RY, et al:Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355:1419-1431.

治療と副作用

P.184 掲載の参考文献

• 1) Vogel F. Moderne probleme der Humangenetik, Ergeb Inn Med Kinderheilkd. Med Kinderheilkd 1959;12:52.

• 2) Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529.
  pubmed

• 3) 薬食審査題0318001号

• 4) Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis:a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenetics & Genomics 2007;17:383.
  pubmed

• 5) Kim SK Jun JB, El-sohemy, et al. Cost-Effectiveness Analysis of MTHFR Polymorphism Screening by Polymerase Chain Reaction in Korean Patients with Rheumatoid Arthritis Receiving Methotrexathe. Journal of Rheumatology 2006;33:7, 1266-1274.
  pubmed

• 6) Evans DAP, et al. Genetic control of isoniazid metabolism in man. Br Med J 1960;2:485.

• 7) http://louisville.edu/medschool/harmacolo/NAT.html

• 8) Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifanpicin-induced heptotoxicity. Int. J Tuberc Lung Dis 2000;4:256-261.

P.191 掲載の参考文献

• 1) Steinmeyer J. Pharmacological basis for the therapy of osteoarthritis. Osteoarthritis-Fundamentals and Strategies for Joint-Preserving Treatment, (Eds Gritka J, Ogilvie-Harris DJ), Berlin, Springer, 2000, p54-65.

• 2) Abadie E, Ethgen D, Avouac B, et al. Group for the Respect of Excellence and Ethics in Science, Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthr. Cartil 2004;12:263-268.

• 3) Steinmeyer J, Konttinen Yr. Oral treatment options for degenerative joint disease-presence and future. Advanced Drug Delivery Reviews 2006;58:168-211.

• 4) Sadowski T, Steinmeyer J. Effects of polysulfated glycosaminoglycan and triamcinolone acetonid on the production of proteinases and their inhibitors by IL-lalpha treated articular chondrocytes. Biochem Phaemacol 2002;64:217-227.

• 5) Verdonk P, Wang J, Elewaut D, et al. Cyclodextrin polysulphates enhance human chondrocyte extracellular matrix repair. Osteoarthritis Cart 2005;13:887-895.

• 6) Uebelhart D, Malaise M, Marcolongo R, et al, Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate:a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil 2004;12:269-276.

• 7) Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate:S/DMOAD (structure/disease modifying anti-osteo-arthritis drug) in the treatment of finger joint OA. Osteoarthr Cartil 1998;6 (Suppl):37-38.

• 8) Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. A randomized, controlled trial. Arthritis Rhetlm 2005;52:779-786.
  pubmed

• 9) Gouze JN, Bianchi A, Becuwe P, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a reseptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett 2002;510:166-170.

• 10) Shikhman AR, Kuhn K, Alaaeddine N, et al. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol 2001;166:5155-5160.
  pubmed

• 11) Piperno N, Reboul P, Hellio Le Graverand MP, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cart 2000;8:207-212.

• 12) Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cart 2003;11:290-298.

• 13) Nakamura H, Shibakawa A, Tanaka M, et al. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004;22:293-299.
  pubmed

• 14) Gouze JN, Bordji K, Gulberti S, et al. Interletlkin-1beta downregulates the expression of gltlcuronosyl-transferase I, a key enzyme priming glycosaminoglycan biosynthesis:influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum 2001;44:351-360.

• 15) Fenton JI, Chlebek-Brown KA, Peters TL, et al. Glucosamine HCL reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cart 2000;8:258-265.

• 16) Fenton JI, Chlebek-Brown KA, Caron JP, et al. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J Suppl 2002;34:219-223.
  pubmed

• 17) Tung JT, Venta PJ, Eberhart SW, et al. Effects of anti-arthritis preparations on gene expression and enzyme activity of cyclooxygenase-2 in cultured equine chondrocytes. Am J Vet Res 2002;63:1134-1139.
  pubmed

• 18) Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cart 2003;11:424-432.

• 19) Sandy JD, Gamett D, Thompson V, et al. Chondrocytemediated catabolism of aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
  pubmed

• 20) Patwari P, Kurz B, Sandy JD, et al. Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage. Arch Biochem Biophys 2000;374:79-85.
  pubmed

• 21) Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans:a review of effects on glucose metabolism, side effects, safety considerations and efflcacy. Food Chem Toxicol 2005;43:187-201.
  pubmed

• 22) McAlindon TE, LaValley MP, Gulin JP. et al. Glucosamine and chondroitin for treatment of osteoarthritis:a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-1475.
  pubmed

• 23) Towheed TE, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis (Cochrane Review), The Cochrane Library, Issue 3, 0xford, 2003, Update Software.

• 24) Cibere J, Kopec JA Thome A, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004;51:738-745.

• 25) Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002;41:279-28, 4.

• 26) Rindone JP, Hiller D, Collacott E, et al. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-94.
  pubmed

• 27) Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis:a randomized double blind controlled 3 month clinical trial. J. Rheumatol 2001;28:1347-1355.
  pubmed

• 28) Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 18 (2) ;CD002946.
  pubmed

• 29) Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression:a randomized, placebo-controlled clinical trial. Lancet 2001;357:251-256.
  pubmed

• 30) Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis:a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-2123.
  pubmed

• 31) Mazzuca SA, Brandt KD, Lane KA, et al. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002;46:1223-1227.
  pubmed

• 32) Buckland-Wright JC, Wolfe F, Ward RJ, et al. Substantial superiority of seminexed (MTP) views in knee osteoarthritis:acomparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999;26:2664-2674.

• 33) Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
  pubmed

• 34) 井上康二. OAとサイトカイン. リウマチ病セミナー, VIII (七川歡次監修), 1997, p174-180, 大阪, 永井書店.

• 35) Pelletier JP, Mineau F, Fernandes JC, et al. Diacerhein and rhein reduce the interleukinlbeta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes, J Reumatol 1998;25:2417-2424.

• 36) Martel-Pelletier J, Mineau F, Jolicoeur FC, et al. In vitro effects of diacerheln and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 1998; 25:753-762.
  pubmed

• 37) Moore AR, Greenslade KJ, Alam CA, et al. Effects of diacerhein on granuloma induced canilage breakdown in the mouse. Osteoarthr. Cartil. 1998;6:19-23.

• 38) Tamura T, Kosaka N, Ishikawa J, et al. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1,-3,-9 and-13 and up-regulates the production of tisstle inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthr. Cartil 2001;9:257-263.

• 39) Mendes AF, Caramona MM, de Cavalho AP, et al. Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol Toxicol 2002 ;91:22-28.

• 40) Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee:a doubleblind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43:2339-2348.

• 41) Dougados M, Nguyen M, Berdah L, et al. ECHODIAH investigators Study Group, Evaluation of the structure modifying effects of diacerein in hip osteoarthritis:ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001;44:2539-2547.

• 42) Yasui T, Adatsuka M, Tobetto K, et al. The effect of hyaluronan on interleukin-1-a-induced prostaglandin-E2 production in human osteoarthritis synovial cells. Agents Actions 1992;37:155-156.

• 43) Tobetto K, Uasui T, Ando T. Inhibitory effects of hyaluronan on (14C) arachidonic acid release from labeled human synovial fibroblasts. Jpn J pharmacol 1992;60:79-84.

• 44) Larsen NE, Lombard KM, Parent EG, et al. Effect of hylan on cartilage and chondrocyte cultures. J Orthop Res 1992;10:23-32.
  pubmed

• 45) Presti D, Scott JE. Hyaluronan mediated protective effect against cell damage caused by enzymatically generated hydroxyl radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct 1994;12:281-288.
  pubmed

• 46) Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis:mechanisms of action. Arthritis Res Ther 2003;5:54-67.
  pubmed

• 47) Lo GH, Valley ML, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis. A meta-analysis. JAMA. 2003;290:3115-3121.

• 48) Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology 2002; 41:1240-1248.
  pubmed

• 49) Goldberg W, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee;evidence for diseasemodifying activity. Osteoarthritis Cartilage 2005;13:216-224.

• 50) Williams JM, Plaza V, Hui F, et al. Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis;II. in vivo. Osteoarthritis Cartilage 1997;5:235-240.

• 51) Homandberg GA, Hui F, Wen C, et al:Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis;Lin vitro. Osteoarthritis Cartilage 1997;5:309-319.

• 52) Kikuchi T, Shinmei M. Effects of hyaluronan on proteoglycan metabolism of rabbit articular chondrocytes in cultures. Jpn J Rheumatol 1994;5:207-215.

• 53) Kikuchi T, Yamada H, Fujikawa K. Effects of high molecular weight hyaluronan on the distribution and movement of proteoglycan around chondrocytes cultured in alginate beads. Osteoarthritis Cartilage 2001;9:351-356.
  pubmed

• 54) Takahasi K, Goomer RS, Harwood F, et al. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1β (IL-β and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. O steoarthritis Cartilage 1999;7:182-190.

• 55) Kalaci A, Yilmaz HR, Aslan B, et al. Effects of hyaluronan on nitric oxide levels and superoxide dismutase activities in synovial fluid in knee osteoarthritis. Clin Reumatol 2007;26:1306-1311.

• 56) Wang CT, Lin YT, Chiang BL, et al. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006;14:1237-1247.
  pubmed

• 57) Stitik TP, Levy JA. Viscosupplementation (Biosupplementation) for Osteoarthritis. Am J Phys Med Rehabil 2006;85 (Suppl):S32-S50.

• 58) Stitik TP, Blacksin MF, Stiskal DM, et al. Efficacy and safety of hyaluronan treatment in combination therapy with home exercise for knee osteoarthritis pain. Arch Phys Med Rehabil 2007;88:135-141.
  pubmed

• 59) Waddel DD, Bricker DC. Total knee replacement delayed with hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm.2007;13:113-121.

• 60) Strand V, Conaghan PG, Lohmander LS, et al. An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan prpduct for intra-articular injection in osteoarthritis of the knee. Osteoarthritis cartilage 2006;14:859-866.
  pubmed

• 61) 牛山敏夫. 膝関節症の関節内注射療法. リウマチ病セミナーXII (七川歡次監修), 2001, p211-219, 大阪, 永井書店.

• 62) Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500-730 kDa) in the treatrnent of osteoarthritis:a review of clinical trials with Hyalgan, Int J Clin Pract. 2002;56:804-813.

• 63) Karakurum G, Karakok M, Tarakcioglu M, et al. Comparative effect of intra-articular administration of hyaluronan and/or conisone with evaluation of malondialdehyde on degenerative osteoarthritis of the rabbit's knee. Tohoku J Exp Med 2003;199:127-134.
  pubmed

• 64) Caborn D, Rush J, Lanzer W, et al. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol 2004; 31:333-343.
  pubmed

• 65) Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis. Results of a randomized, placebo-cotrolled, double-blind trial. Arthritis Reumatism 2005;57:2015-2025.

• 66) Khayyal MT, El-Ghazaly MA. The possible"chondroprotective"effect of the unsaponifiable constituents of avocado and soya in vivo. Drugs Explt Clin Res 1998;24:41-50.

P.202 掲載の参考文献

• 1) 川合眞一, 越智隆弘, 近藤啓文, ら.-日本リウマチ財団委員会報告-メトトレキサートおよびサラゾスフファピリジンの臨床容量調査. リウマチ2002;42:76-79.

• 2) 中島亜矢子, 山中 寿. 関節リウマチの標準薬としてMTX. リウマチ科2004;32:223-228.

• 3) 福田孝昭. 関節リウマチに対するMTX処方治療調査. リウマチ科2004;32:243-247.

• 4) American College of rheumatology subcommittee on rheumatoid arthritis guideline. Guidelines for the management of rheumatoid arthritis:2002 Update. Arthritis Rheum 2002;46:329-346.

• 5) Weinblatt ME JS, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatiod arthritis. N Engl J Med 1985;312:818-822.

• 6) Hall GH, Head AC. Letter:Intra-articular methotrexate. Lancet 1975;2(7931):409.
  pubmed

• 7) Marks JS, Stewart IM, Hunter JA. Intra-articular methotrexate in rheumatiod arthritis. Lancet 1976;2 (7990):857-858.

• 8) Hall GH, Jones BJ, Head AC, et al. Intra-articular methotrexate. Clinical and laboratory study in rheumatiod and psoriatic arthritis. Ann Rheum Dis 1978;37 (4):351-335.

• 9) Franchi FP, Seminara P, Codacci-Pisanelli G, et al. Intrarticular methotrexate in the therapy of rheumatoid arthritis. Recenti Prog Med 1989;80(5):261-262.

• 10) 荒井 毅, 井上四朗, 茨木和博, ら. 膝関節水腫を伴う慢性関節リウマチ患者のMTX (メソトレキサート) 関節注入療法の効果. 中部日本整形災害外科学会雑誌1990;33:862-864.

• 11) 荒井 毅, 大橋俊郎, 谷 和久, ら. 慢性関節リウマチに対するMTX関節注を用いたStep-dowm Bridge Treatment療法. 中部リウマチ1993;24:184-185.

• 12) Nakaya H, Shimizu T, Isobe K, et al. Microbubble-enhanced ultrasound exposure promotes uptake of methotrexate into synovial cells and enhanced anti-inflammatory effects in rabbit antigen-induced arthritic knees. Arthritis Rheum 2005;52:2559-2566.

P.211 掲載の参考文献

• 1) Grillo-L pez AJ, White CA, Dallaire BK, et al. Rituximab:the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000;1:1-9.

• 2) Grillo-L pez AJ. Rituximab (Rituxan/MabThera):the first decade (1993-2003) . Expert rev anticancer ther 2003 ;3:767-779.

• 3) 飛内賢内. 悪性リンパ腫の抗体療法 Biotherapy 2006;20:123-131.

• 4) 小椋美知則:リンパ腫に対する抗体療法 がん分子標的治療2006;4:114-128.

• 5) Cartron G, Watier H, Golay J, et al. From the bench to the bedside:ways to improve rituximab efficacy. Blood 2004;104:2635-2642.

• 6) Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis:emerging patterns and paradigms. Arthritis Rheum 2006;54:2356-2367.
  pubmed

• 7) Ternant D, Paintaud G:Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion protteins. Expert Opin Biol Ther 2005;5 (suppl1):S37-S47.

• 8) Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758.
  pubmed

• 9) Eisenberg, R, Looney, RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 2005; 117:207-213.

• 10) Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-826.

• 11) van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811.

• 12) Cvetkovic RS, Perry CM. Rituximab:a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791-820.
  pubmed

• 13) Mohrbacher, A. B cell non-Hodgkin's lymphoma:rituximab safety experience. Arthritis Res Ther 2005;7 (Suppl 3):S19-25.

• 14) Kimby E:Tolerability and safety of rituximab (MabThera) . Cancer Treat Rev 2005;31:456-473.
  pubmed

• 15) Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106:795-802.
  pubmed

• 16) Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
  pubmed

• 17) Smith, MR. Rituximab (monoclonal anti-CD20 antibody):mechanisms of action and resistance. Oncogene 2003 ;22:7359-7368.
  pubmed

• 18) Brezinschek HP, Brickmann K, Yazdani-Biuki B, et al. Treatment of rheumatoid arthritis in the 21st century:targeting B-lymphocytes. Wien Med Wochenschr 2006;156:61-67.
  pubmed

• 19) Browning JL. B cells move to centre stage:novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5:564-576.
  pubmed

• 20) Edwards, JC, Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
  pubmed

• 21) Shaw, T, Quan, J, Totoritis, MC. B cell therapy for rheumatoid arthritis:the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62 (Suppl 2):ii55-59.

• 22) Edwards JC, Cambridge G. Rheumatoid arthritis:the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998;37:126-130.
  pubmed

• 23) Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines:a role in immune regulation? J Immunol 2004;172:3422-3427.

• 24) Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-4718.

• 25) Protheroe A, Edwards JC, Simmons A, et al. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkinls lymphoma. Rheumatology (Oxford) 1999;38:1150-1152.
  pubmed

• 26) Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-211.
  pubmed

• 27) Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with Blymphocyte depletion. Ann Rheum Dis 2002;61:883-888.

• 28) De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis:evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-2033.
  pubmed

• 29) Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.
  pubmed

• 30) Cohen SB. Updates from B Cell Trials:Efficacy. J Rheumatol (Suppl) . 2006;77:12-17.

• 31) Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment:results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400.
  pubmed

• 32) Cohe, SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806.

• 33) Panayi GS. B cell-directed therapy in rheumatoid arthritis-clinical experience. J Rheumatol (Suppl) 2005;73:19-24;discussion 29-30.

• 34) Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-1939.

• 35) Smolen JS, Betteridge N, Breedvel, FC, et al. Consensus Statement on the Use of Rituximab in Patients With Rheumatoid Arthritis. Ann Rheum Dis 2007;66:43-150.

• 36) Breedveld FD, Kim D, Agarwal S, et al. Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab[abstract]. Ann Rheum Dis 2006;65 (Suppl 2):THU0206.

• 37) Eisenberg R. Update on rituximab. Ann Rheum Dis 2005;64 Suppl 4:iv55-57.

• 38) Westwood OM, Nelson PN, Hay FC:Rheumatoid factors:what:s new? Rheumatology (Oxford) 2006;45:379-385.

P.224 掲載の参考文献

• 1) 宗圓 聡, 神谷正人, 菊池啓, ら. RAにおける全身性骨粗鬆症の診断基準に関する検討. 臨床リウマチ 2001 ;13:190-195.

• 2) 中山久徳. 関節リウマチと骨粗鬆症. Modern Physician 2005;25:757-761.

• 3) Hooyman JR, Melton LJ 3rd, Nelson AM, et al. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 1984;27:1353-1361.
  pubmed

• 4) Michel BA Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis:an evaluation of associated risk factors. J Rheumatol 1993;20:1666-1669.
  pubmed

• 5) Pentecost RL, Murray RA, Brindley HH, et al. Fatigue, Insuthciency, and Pathologic Fractures. JAMA 1964; 187:1001-1004.
  pubmed

• 6) Schneider R, Kaye JJ, et al. Insufficiency and stress fractures of the long bones occuning in patients with rheumatoid arthritis. Radiology 1975;116:595-599.

• 7) Fam AG, Shuckett R, McGillivary DC, et al. Stress fractures in rheumatoid arthritis. J Rheumatol 1983;10:722-726.

• 8) West SG, Troutner JL, Baker MR, et al. Sacral insufficiency fractures in rheumatoid arthritis. Spine 1994;19:2117-2121.

• 9) Young A, Kinsella P, Boland P. Stress fractures of the lower limb in patients with rheumatoid arthritis. J Bone Joint Surg Br 1981;63-B:239-243.

• 10) Alonso-Bartolome P, Martinez-Taboada VM, Blanco R, et al. Insufficiency fractures of the tibia and fibula. Semin Arthritis Rheum 1999;28:413-420.
  pubmed

• 11) 橋本淳, 南平昭豪, 小柳淳一朗, ら. 続発性骨粗鬆症の病態と治療. RAおよびステロイド性骨粗鬆症に伴う骨折の特徴. 日本リウマチ学会総会. 学術集会抄録集2006;p50.

• 12) Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fractuer risk. Osteoporosis Int 2005;16:581-589.
  pubmed

• 13) 宗圓 聡, 神谷正人, 菊池 啓, ら. RAにおける全身性骨粗鬆症の診断基準に関する検討. 臨床リウマチ 2001;13:190-195.

• 14) Nawata H, Soen S, Takayanagi R, et al. The Subcomittie to Study Diagnostic Criteria for Glucocorticoid-induced Osteoporosis:Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of Japanese Society for Bone and Mineral Research (2004), JBone Miner Metab 2005;23:105-109.

P.233 掲載の参考文献

• 1) 文部科学省:新体力テスト, 東京:ぎょうせい;2002:pp125.

• 2) Mathias S, Nayak US, Isaacs B. Balance in elderly patients:the"Get-up and Go"test. Arch Phys Rehabil 1986;67:387-389.
  pubmed

• 3) Podsiadlo D, Richardson S. The timed"Up&Go":a test of basic functuional mobility for frail elderly persons. JAGS 1991;39:142-148.

• 4) Shimada K, Ozawa T, Matsubayashi K:Dependency of the aged in the community. Lancet 1993;342:1241.
  pubmed

• 5) 坂田悍教. 高齢者の寝たきりの原因の解明及び予防に関する研究. 厚生労働省長寿科学総合研究事業平成14年度報告書, 2003;p24-33.

• 6) 奥泉宏康, 武藤芳照, 黒柳律雄, ら. 転倒予防教室における転倒と身体能力の関係. 骨折2005;27:97-101.

• 7) 鈴木隆雄ほか:地域高齢者における転倒と転倒恐怖感についての研究-要介護予防のための包括的健診 (「お達者健診」) の調査より. Osteoporosis Jpn 2004;12:295-298.

• 8) 高齢者リハビリテーションのあるべき方向. 平成16年1月社会保険研究所 http://www.mhlw.go.jp/shigi/2004/03/s0331-3.html

• 9) 北 潔, 新村秀幸, 浅井 剛, ら. 開眼片脚起立時間からみた運動器不安定症. 臨整外2006;41:757-763.

• 10) Kita K Hujino K, Nasu T, et al. A simple protocol for preventing falls and fractures in elderly individuals with musculoskeletal disease. Osteopors Int 2007 (in press).

• 11) Isles RC, Choy NLL, Steer M, Nitz JC. Normal values of balance tests in women aged 20-80. JAGS 2004;52:1367-1372.

• 12) Akai M, Iwaya T, Kurosawa H et al. (2006) Straight leg raising exercise for knee osteoarthritis:Randomized controlled trial. J Jpn Orthop Assoc 80:316-320.

• 13) 阪本桂造:整形外科的立場から-ダイナミックフラミンゴ療法など. 臨床スポーツ医学1998;15 831-836.

• 14) Hirschberg GG. The use of stan (1-up and step-tlp exercises in rehabilitation. Clin Orthop 1958;12:30-38.

• 15) 北 潔, 吉矢晋一:新しく考案した高齢者に対する1分間腕立て訓練と上肢外転敏捷性テスト (羽ばたきテスト) . 運動・物理療法2005;16:25-32.

• 16) 北 潔, 佐浦隆一, 西林保朗, ら. 運動器虚弱高齢者に対する転倒介護予防. 整形・災害外科2005;48:697-704.

• 17) 宮野佐年. 運動負荷とそのリスク. リハ医学1995;32:301-306.

• 18) Latham NK, Anderson CS, Lee X et al. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people:The frailty intervention trial in elderly subjects (FITNESS) . JAGS 2003;51:291-299.

• 19) Jette AM, Lachman M, Giorgetti MM, et al:Exercise-lt's never too late:The strong-for-life program. Am J Public Health 1999;89:66-72.

P.241 掲載の参考文献

• 1) リウマチ患者の実態 (資料編) 2005年リウマチ白書. 流242号 ふろく (日本リウマチ友の会編) . 2005, p11-79, 障害者団体定期刊行物協会.

• 2) 小松原良雄. 関節リウマチの治療方法の進展と経過の変化についてリウマチ病セミナー XVII (七川歡次監 修), 2006, p134-139, 大阪, 永井書店.

• 3) 小松原良雄. 慢性関節リウマチ患者の妊娠と出産. リウマチ病セミナーX (七川歡次監修), 1999, p263-272, 大阪:永井書店.

• 4) 大阪骨・関節難病研究会. 大阪府における慢性関節リウマチの実態調査. 昭和50年度骨. 関節難病調査研究結果報告書. 1976, p7-41, 大阪府衛生局.

• 5) 七川歡次, 前田晃, 広瀬俊一, ら. 慢性関節リウマチ患者の実態に関する調査研究. 昭和63年度厚生科学研究費補助金 (特別研究事業) 事業成績報告書, 1988.

• 6) 村田紀和. リハビリテーション:診断のマニュアルとEBMに基づく治療ガイドライン:(越智隆弘, ら編), 2004, p143-154, 日本リウマチ財団.

• 7) 今野孝彦, ら. 関節リウマチ患者の在宅生活への支援 (今野孝彦編), 2006, p1-205, 東京, メディカルトリビューン.

• 8) 村澤 章. リウマチ性疾患に対する社会的支援. リウマチ基本テキスト (日本リウマチ財団教育研修委員会編):日本リウマチ財団;2002:p577-590.

• 9) 松野博明. 介護保険の書類作成法. リウマチ膠原病診療実践マニアル第2版 (後藤 真編) 2004, p413-417, 東京, 文光堂.

• 10) 松野博明. 身体障害者の診断書作成法. ステップアップリウマチ膠原病診療 (後藤 真編) 2000, p396-418, 東京, 文光堂.

手術

P.255 掲載の参考文献

• 1) Wroblewski BM. Chamley low-friction arthroplasty. Review of the past, present status, and prospects for the future. Clin Orthop Relat Res 1986;210:37-42.

• 2) Oh I, Carlson CE, Tomford W, et al. Improved fixation of the femoral component after total hip replacement using a methacrylate intramedullary plug. J Bone Joint Surg Am 1978;60:608-613.
  pubmed

• 3) Mulroy RD Jr, Harris WH. The effect of improved cementing techniques on component loosening in total hip replacement. An 11-year radiographic review. J Bone Joint Surg Br 1990;72:757-760.
  pubmed

• 4) Madey SM, Callaghan JJ, Olejniczak Jp, et al. Charnley total hip arthroplasty with use of improved techniques of cementing. The results after a minimum of fifteen years of follow-up. J Bone Joint Surg Am 1997;79:53-64.
  pubmed

• 5) Schulte KR, Callaghan JJ, Kelley SS, et al. The outcome of Charnley total hip arthroplasty with cement after a minimum twenty-year follow-up. The results of one surgeon. J Bone Joint Surg Am 1993;75:961-975.

• 6) Sochart DH, Porter ML. The long term results of Charnley total hip arthroplasty in young patients who have congenital dislocation, degenerative osteoarthritis, or rheumatoid arthritis. J Bone Joint Surg Am 1997;79:1599-1617.
  pubmed

• 7) Callaghan JJ, Forest EE, Olejniczak Jp, et al. Charnley total hip arthroplasty in patients less than fifty years old. Atwenty to twenty-five-year follow-up note. J Bone Joint Surg Arn 1998;80:704-714.

• 8) MacDonald W, Swarts E, Beaver R. Penetration and shear strength of cement-bone interface in vivo. Clin Orthop Relat Res. 1993;286:283-288.
  pubmed

• 9) Madey SM, Callaghan JJ, Olejniczak JP, et al. Charnley total hip arthroplasty with use of improved techniques of cementing.:The results after a minimum of filiteen years of follow-up.J Bone Joint Surg Am 1997;79:53-64.
  pubmed

• 10) Chou L, Marek B, Wagner WR. Effects of hydroxyapatite coating crystallinity on biosolubility, cell attachment ethciency and proliferation in vitro. Biomaterials 1999;20:977-985.
  pubmed

• 11) DeLee JG, Charnley J. Radiological demarcation of cemented sockets in total hip replacement. Clin Orthop Relat Res 1976;121:20-32.
  pubmed

• 12) Engh CA Jr, Young AM, Engh CA Sr, et al. Clinical consequences of stress shielding after porous-coated total hip arthroplasty. Clin Orthop Relat Res 2003;417:157-163.
  pubmed

• 13) Geesink RG. Osteoconductive coatings for total joint anhroplasty. Clin Orthop Relat Res. 2002;395:53-65.
  pubmed

• 14) Puolakka TJ, Pajamaki KJ, Halonen PJ,et al. The Finnish Arthroplasty Register, Report of the hip register. Acta Orthop Scand 2001;72:433-441.
  pubmed

• 15) Malchau H, Herberts P, Eisler T, et al.:The Swedish Total Hip Replacement Register. J Bone Joint Surg Am:84-A 2002;2:2-20.

• 16) Havelin L, Engesaeter L, Espehang B. The Norwegian Arthroplasty Register, 11 years and 73, 000 arthroplasties. Acta Orthop Scand 2000;71:337-353.

• 17) Malchau H, Herberts P. Prognosis of total hip replacement, In Scientific exhibition presented at the 63rd annual meeting of the American academy of orthopaedic surgeons, Atlanta, USA American academy of orthopaedic surgeons, 1996, p1-16.

• 18) Oonishi H, Fujita Y, Kin S, et al. Interface bioactive bone cement (IBBC) in place of HA coating:Merits and demerits. Bioceramics 14, Key Engineering Materials 2002;218-220:357-360.

• 19) Oonishi H, Kushitani S, Aono M, et al. Interface bioactive bone cement by using PMMA and hydroxyapatite granules. In:Bioceramics 1 (Ed. Oonishi and Aoki), Tokyo, Ishiyaku-Euro America, 1989, p102-107.

• 20) Oonishi H. Interfacial reactions to bioactive and non-bioactive bone cements. In The bone biomaterial interface (Ed. Davis JE), Toront, University of Toronto Press, 1991, p321-324.

• 21) Oonishi H, Kadoya Y, Iwaki H, et al. Total hip arthroplasty with a modified cementing technique using hydroxyapatite granules. J Arthroplasty 2001;16:784-789.
  pubmed

• 22) Oonishi H, Kadoya Y, Iwaki H, et al. Hydroxyapatite granules interposed at bone-cement interface in total hip replacements:histological study on retrieved specimens. J Appl Biomat 2001;53:174-180.

• 23) 大西啓靖, 金石哲, Ian C. Clarke, ら:人工関節はここまで進歩している, 現在医療の最前線-人工臓器とメディカルエンジニアリングの進歩-. 最新医学2003年6月増刊号, 2003, p1400-1424, 大阪, 最新医学社.

• 24) 大西啓靖, 金石哲, 土井口祐一, ら:超長期耐用しうる人工関節に求められる傾斜機能特性, 新材料シリーズ, 傾斜機能材料の開発と応用, 2003, p159-173 , 東京, シーエムシー出版.

• 25) 大西啓靖, 金石哲, 高尾康裕 ら, 超長期耐用しうる人工関節の固着法-界面バイオアクティブ骨セメント法-シリーズ), 骨・関節・靱帯, 2005;18, 1, 9-16, 東京, アークメディア.

P.266 掲載の参考文献

• 1) Foley Kr and Smith MM. Microendoscopic Discectomy. Techniques in Neurosurgery 1997;3:301-307.

• 2) 吉田宗人, 玉置哲也, 岩崎 博, ら. 内視鏡視下腰椎椎間板摘出術 (MED法) の低侵襲性の評価-MED法とLove法の比較-. 臨整外2001;36:497-452.

• 3) 吉田宗人, 中川幸洋, 麻埴生和博, ら. 後方進入脊椎内視鏡視下手術の適応と臨床成績-315例の検討-. 臨整外2004;39:563-569.

• 4) 山縣正庸, 守屋秀繁, 高橋和久, ら. 内視鏡下腰椎椎間板ヘルニア摘出術の試み. 関節鏡1998;23:115-119.

• 5) 小池承彦, 出沢 明. 後方椎間板ヘルニア摘出-10cc注射器 (endoLove法) . (松井宣夫, 出沢 明編), 整形外科関節鏡マニュアル 脊椎内視鏡, 2000, 152-157, 東京, メジカルビュー社.

• 6) 山縣正庸. 腰椎椎間板ヘルニアの鏡視下摘出術. 脊椎脊髄ジャーナル2004;6:657-662.

• 7) 生田 光, 田中孝幸, 合志光平, ら. 後方進入脊椎内視鏡視下手術の短期成績と問題点. 臨床整形外科 2005;40:989-997.

• 8) 夏山元伸, 熊野 潔, 町田秀人, ら. MEDの新しい適応範囲の拡大 腰椎椎間板ヘルニア再手術と腰部脊柱管狭窄症の除圧手術への応用. 脊椎・脊髄神経手術手技2003;5:31-34.

• 9) 吉田宗人. 内視鏡視下手術の応用 「腰部脊柱管狭窄症-治療と診断のニューコンセプト」. 整形外科2002; 53:1096-1103.

• 10) 吉田宗人, 麻埴生和博, 角谷昭, , ら. 腰部脊柱管狭窄症に対する内視鏡視下後方除圧手術 片側進人両側除圧法. 脊椎・脊髄神経手術手技2003;5:35-38.

• 11) 吉田宗人, 山田 宏, 麻埴生和博, ら. 整形外科における関節以外の内視鏡手術 頸椎疾患に対する後方進入内視鏡視下手術の展望. 整形・災害外科2004;47:1461-1467.

• 12) 吉田宗人. Microendoscopic discectomy手術手技の実際/関節鏡手術-最近の進歩. 臨床整形外科2002; 37:1167-1175.

• 13) 中谷如希, 吉田宗人, 南出晃人, ら. ナビゲーション手術の現状 (脊椎) 腰部脊柱管狭窄症に対する後方進入鏡視下開窓術におけるナビゲーションシステムの有用性. 中部整災雑誌2005;48 (suppl):111.

P.276 掲載の参考文献

• 1) Ferris BD, Kennedy C, Bhamra, M et al. Morphology of the femur in proximal femoral fractures. J Bone Joint Surg 1989;71-B:475-477.

• 2) 日本整形外科学会骨粗鬆症委員会. 平成10年大腿骨頸部骨折の発生頻度調査. 日整会誌2000;74:373-377.

• 3) 日本整形外科学会骨粗鬆症委員会. 平成10年大腿骨頸部骨折の発生頻度調査. 日整会誌2001;75:387-402.

• 4) 萩野 浩. 大腿骨頸部骨折の疫学. MB Orthop 2003;16:1-7.

• 5) 萩野 浩, 阪本桂造. 大腿骨頸部骨折対策-全国調査結果からの考察-. 関節外科2003;22:24-27.

• 6) Neyens JCL, Dijcks BPJ, van Haastregt JCM, et al. The development of a multidisciplinary fall risk evaluation tool for demented nursing home patients in the Netherlands. BMC Public Health 2006;6:74. Published online 2006 March 21. dol:10.1186/1471-2458-674.

• 7) Rubenstein LZ, Josephsonn KR, Robbins AS. Falls in the nursing home. Ann Intem Med 1994;121:442-451.

• 8) Sakamoto K, Nakamura T, Hagino H, et al. Report on the Japanese Orthopaedic Association's 3-year project observing hip fractures at nxed-point hospitals. J Orthop Sci 2006;11:127-134.
  pubmed

• 9) 阪本桂造, 萩野 浩, 中村利孝, ら. 骨粗鬆症関連骨折の予後と予防. 日整会誌2006;80:S367.

• 10) Dahl E. Mortality and life expectancy after hip fractures. Acta Orthop Scand 1980;51:163-170.
  pubmed

• 11) Ravikumar KJ, Marsh G. Internal fixation versus hemiarthroplasty versus total hip arthroplasty for displaced subcapital fractures of femur:13 year results of a prospective randomised study. Injury, Int J Care Injured 2000;31:793-797.

• 12) Fox KM, Magajiner J, Hebel JR, et al. Intertrochanteric versus femoral neck hip fractures:differential characteristics, treatment, and sequelae. J Gerontol Med Sci 1999;54A:M635-M640.

• 13) Hamlet WP, Lieberman JR, Freedman EL et al. Influence of health status and the timing of surgery on mortality in hip fracture patients. Am J Orthop 1997;26:621-627.
  pubmed

• 14) Jennings AG, de Boer P. Should we operate on nonagenarians with hip fractures? Injury, Int J Care Injured 1999;30:169-172.

• 15) EIIiott J, Beringer T, Kee F, et al. Predicting survival after treatment for fracure of the proximal femur and the effect of delays to surgery. J Clin Epidemiol 2003;56:788-795.

• 16) Kyo T, Takaoka K, Ono K Femoral neck fracture:factors related to ambulation and prognosis. Clin Orthop 1993;292:215-222.
  pubmed

• 17) 大谷晃司, 猪股洋一郎. 高齢者大腿骨頸部骨折の術後成績からみたリスクマネージメント. MB Ortho 2003;16:63-70.

• 18) 渡辺航太, 松村崇史, 相羽 整, ら. 大腿骨頸部骨折に対する人工骨頭置換術後の予後について-歩行能力, 生命予後を中心に-整形外科2003;54:1137-1140.

• 19) Kitamura S, Hasegawa Y, Suzuki S, et al. Functional outcome after hip fracture in Japan. Clin Orthop 1988; 348:29-36.

• 20) 岸 陽子, 浦岡秀行. 予後から見た高齢者大腿骨頸部骨折の治療方針. 中部整災誌2003;46:1037-1038.

• 21) 石橋英明:大腿骨頸部骨折患者の生命予後. MB Orthop 2003;16:1523.

• 22) 今西理恵子, 市村和徳, 石井佐宏. 病院, 介護施設内で受傷した高齢者大腿骨近位部骨折の予後. 整形外科2004;55:353-355.

• 23) 鈴木裕彦:大腿骨頸部内側骨折に対する人工骨頭置換術とその成績. Clin Calcium 2003;13:1323-1328.

• 24) van Dortmont LMC, Douw CM, van Breukelen AMA, et al. Outcome after hemi-arthroplasty for displaced intracapsular femoral neck fracture related to mental state. Injury, Int J Care Injured 2000;31:327-331.

• 25) Hudson JI, Kenzora JE, Hebel JR, et al. Eight-year outcome associated with clinical options in the management of femoral neck fractures. Clin Orthop 1998;348:59-66.
  pubmed

• 26) 藤田英彦, 伊藤 淳. 大腿骨頸部骨折手術後の歩行能力維持に影響を及ぼす痴呆関連因子について. 関東整災誌2003;34:362-366.

• 27) 萩野 浩, 渡辺欣忍, 中野哲雄, ら. 大腿骨頸部骨折診療ガイドライン. 日整会誌2005;79:298-304.

• 28) Dihlman W. Joints and vertebral connections. New York, Thieme Inc. 1985.

• 29) 萩野 浩. 骨折の疫学-年次推移・国際比較・危険因子-. Clin Calcium 2003;13:995-1002.